Sagar Lonial MD
Overview
Sagar Lonial, MD, is Professor and Chair of the Department of Hematology and Medical Oncology at Emory University School of Medicine where he also holds the Anne and Bernard Gray Family Chair in Cancer.
Internationally recognized as a leading authority in multiple myeloma treatment and research, Dr. Lonial collaborates with leadership as Chief Medical Officer to coordinate and enhance clinical services and patient care throughout Winship Cancer Institute of Emory University.
Dr. Lonial is involved in numerous professional organizations including American Society of Clinical Oncology, American Society of Hematology, and American Society for Blood and Marrow Transplantation. He serves Vice Chair of the Finance Committee of the International Myeloma Society, and serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group. He also serves as President and Chair of the Society of Hematologic Oncology. Additionally, he is on the Scientific Advisory Board for the International Myeloma Foundation.
Dr. Lonial has authored or coauthored over 200 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology, Leukemia, is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and is the hematologic malignancies section editor for the journal Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others.
Academic Appointment
- Professor of Hematology and Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute
Education
Degrees
- MD from University of Louisville School of Medicine
- BA from The Johns Hopkins University
Research
Focus
- A major focus of the Lonial lab is the development of novel single agents or combinations of novel agents with the intent of more effective targeted therapy for myeloma and lymphoma.
Publications
-
Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myeloma.
Biomaterials Volume: 316 Page(s): 123016
05/01/2025 Authors: Ghoshal D; Petersen I; Ringquist R; Kramer L; Bhatia E; Hu T; Richard A; Park R; Corbin J; Agarwal S -
Correction: The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.
Blood Cancer J Volume: 15 Page(s): 44
03/26/2025 Authors: Mukhopadhyay P; Abdullah HA; Opalinska JB; Paka P; Richards E; Weisel K; Trudel S; Mateos M-V; Dimopoulos MA; Lonial S -
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.
Blood Volume: 145 Page(s): 732 - 747
02/13/2025 Authors: Nair R; Vu AH; Freer AK; Bhatia KS; Wang D; Savani MR; Matulis SM; Lonial S; Jaye DL; Boise LH -
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development.
Blood Cancer J Volume: 15 Page(s): 15
02/07/2025 Authors: Mukhopadhyay P; Abdullah HA; Opalinska JB; Paka P; Richards E; Weisel K; Trudel S; Mateos M-V; Dimopoulos MA; Lonial S -
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis.
Blood Volume: 145 Page(s): 75 - 84
01/02/2025 Authors: Banerjee R; Sexton R; Cowan AJ; Rosenberg AS; Ailawadhi S; Rajkumar SV; Kumar S; Dispenzieri A; Lonial S; Durie BGM -
SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination.
Nat Med Volume: 31 Page(s): 235 - 244
01/01/2025 Authors: Nguyen DC; Hentenaar IT; Morrison-Porter A; Solano D; Haddad NS; Castrillon C; Runnstrom MC; Lamothe PA; Andrews J; Roberts D -
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.
Blood Cancer J Volume: 14 Page(s): 215
12/05/2024 Authors: Rajkumar SV; Mateos M-V; Schaeffer M; Lin X; Bathija S; Gupta-Werner N; Lam A; Carson R; Dennis R; Kaila S -
A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.
Clin Cancer Res Volume: 30 Page(s): 4844 - 4855
11/01/2024 Authors: Desai P; Lonial S; Cashen A; Kamdar M; Flinn I; O'Brien S; Garcia JS; Korde N; Moslehi J; Wey M -
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity.
NPJ Vaccines Volume: 9 Page(s): 201
10/27/2024 Authors: Moreno A; Manning K; Azeem MI; Nooka AK; Ellis M; Manalo RJ; Switchenko JM; Wali B; Kaufman JL; Hofmeister CC -
How to rescue a DreaMM deferred .
Med Volume: 5 Page(s): 1048 - 1049
09/13/2024 Authors: Joseph NS; Lonial S -
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients.
Blood Cancer J Volume: 14 Page(s): 159
09/13/2024 Authors: Joseph NS; Kaufman JL; Gupta VA; Hofmeister CC; Dhodapkar MV; Boise LH; DiCamillo SM; Roberts D; Nooka AK; Lonial S -
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Nat Genet Volume: 56 Page(s): 1878 - 1889
09/01/2024 Authors: Skerget S; Penaherrera D; Chari A; Jagannath S; Siegel DS; Vij R; Orloff G; Jakubowiak A; Niesvizky R; Liles D -
Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cells.
Nucleic Acids Res Volume: 52 Page(s): 7539 - 7555
07/22/2024 Authors: Cinar M; Martinez-Medina L; Puvvula PK; Arakelyan A; Vardarajan BN; Anthony N; Nagaraju GP; Park D; Feng L; Sheff F -
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA.
Lancet Haematol Volume: 11 Page(s): e510 - e520
07/01/2024 Authors: Khan MK; Nasti TH; Qian JY; Kleber TJ; Switchenko JM; Kaufman JL; Nooka AJ; Dhodapkar MV; Buchwald ZS; Obiekwe D -
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Cell Rep Med Volume: 5 Page(s): 101571
06/18/2024 Authors: Amatangelo M; Flynt E; Stong N; Ray P; Van Oekelen O; Wang M; Ortiz M; Maciag P; Peluso T; Parekh S -
Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival culture.
Sci Rep Volume: 14 Page(s): 3616
02/13/2024 Authors: Nguyen DC; Saney C; Hentenaar IT; Cabrera-Mora M; Capric V; Woodruff MC; Andrews J; Lonial S; Sanz I; Lee FE-H -
Shrinking the divide: improving myeloma CART access.
Blood Adv Volume: 8 Page(s): 248 - 250
01/09/2024 Authors: Nooka AK; Hartley-Brown MA; Anderson KC; Lonial S -
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Blood Cancer Discov Volume: 5 Page(s): 56 - 73
01/08/2024 Authors: Neri P; Barwick BG; Jung D; Patton JC; Maity R; Tagoug I; Stein CK; Tilmont R; Leblay N; Ahn S -
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
Blood Cancer Discov Volume: 5 Page(s): 34 - 55
01/08/2024 Authors: Welsh SJ; Barwick BG; Meermeier EW; Riggs DL; Shi C-X; Zhu YX; Sharik ME; Du MT; Abrego Rocha LD; Garbitt VM -
Glcksklee, the Quad, and High-Risk Myeloma.
J Clin Oncol Volume: 42 Page(s): 1 - 3
01/01/2024 Authors: Nooka AK; Kaufman JL; Lonial S -
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica Volume: 108 Page(s): 2894 - 2912
11/01/2023 Authors: Richardson PG; Durie BG; Rosiol L; Mateos M-V; Dispenzieri A; Moreau P; Kumar S; Raje N; Munshi N; Laubach JP -
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 23 Page(s): 815 - 824
11/01/2023 Authors: Lonial S; Bowser AD; Chari A; Costello C; Krishnan A; Usmani SZ -
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma.
N Engl J Med Volume: 389 Page(s): 1009 - 1022
09/14/2023 Authors: Richardson PG; Trudel S; Popat R; Mateos M-V; Vangsted AJ; Ramasamy K; Martinez-Lopez J; Quach H; Orlowski RZ; Arnao M -
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction.
JCO Oncol Pract Volume: 19 Page(s): 793 - 798
09/01/2023 Authors: Sun LF; Maples KT; Hall KH; Liu Y; Cao Y; Joseph NS; Hofmeister CC; Kaufman JL; Dhodapkar M; Nooka AK -
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.
Blood Cancer Discov Volume: 4 Page(s): 365 - 373
09/01/2023 Authors: Paiva B; Manrique I; Rytlewski J; Campbell T; Kazanecki CC; Martin N; Anderson LD; Berdeja JG; Lonial S; Raje NS -
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.
J Clin Invest Volume: 133
08/01/2023 Authors: Robinson MH; Villa NY; Jaye DL; Nooka AK; Duffy A; McCachren SS; Manalo J; Switchenko JM; Barnes S; Potdar S -
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Blood Cancer J Volume: 13 Page(s): 116
08/01/2023 Authors: Raje N; Anderson K; Einsele H; Efebera Y; Gay F; Hammond SP; Lesokhin AM; Lonial S; Ludwig H; Moreau P -
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses.
Cell Rep Volume: 42 Page(s): 112682
07/25/2023 Authors: Duan M; Nguyen DC; Joyner CJ; Saney CL; Tipton CM; Andrews J; Lonial S; Kim C; Hentenaar I; Kosters A -
Novel approaches to the treatment of multiple myeloma.
Clin Adv Hematol Oncol Volume: 21 Page(s): 247 - 256
05/01/2023 Authors: Maples KT; Scott SA; Lonial S -
Disparities in multiple myeloma among African Americans.
J Natl Med Assoc Volume: 115 Page(s): S26 - S31
05/01/2023 Authors: Bhutani M; Lonial S; Mikhael J -
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.
Blood Cancer Discov Volume: 4 Page(s): 106 - 117
03/01/2023 Authors: Azeem MI; Nooka AK; Shanmugasundaram U; Cheedarla N; Potdar S; Manalo RJ; Moreno A; Switchenko JM; Cheedarla S; Doxie DB -
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
Blood Cancer J Volume: 13 Page(s): 29
02/20/2023 Authors: Maples KT; Hall KH; Joseph NS; Hofmeister CC; Gupta V; Dhodapkar MV; Kaufman JL; Nooka AK; Lonial S -
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Blood Cancer J Volume: 13 Page(s): 14
01/12/2023 Authors: Chng W-J; Lonial S; Morgan GJ; Iida S; Moreau P; Kumar SK; Twumasi-Ankrah P; Villarreal M; Dash AB; Vorog A -
Optimizing the benefits of BCMA-targeted CAR T-cell therapy in multiple myeloma.
Clin Adv Hematol Oncol Volume: 21 Page(s): 43 - 45
01/01/2023 Authors: Lonial S -
Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
CA Cancer J Clin Volume: 73 Page(s): 275 - 285
01/01/2023 Authors: Parikh RH; Lonial S -
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.
Lancet Haematol Volume: 9 Page(s): e822 - e832
11/01/2022 Authors: Lonial S; Popat R; Hulin C; Jagannath S; Oriol A; Richardson PG; Facon T; Weisel K; Larsen JT; Minnema MC -
EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit.
Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S24 - S26
10/01/2022 Authors: Nooka AK; Lonial S -
When an embarrassment of riches isn't enough.
Nat Rev Clin Oncol Volume: 19 Page(s): 617 - 618
10/01/2022 Authors: Patel K; Lonial S -
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
Sci Adv Volume: 8 Page(s): eabq5575
09/30/2022 Authors: Sharma A; Nair R; Achreja A; Mittal A; Gupta P; Balakrishnan K; Edgar CL; Animasahun O; Dwivedi B; Barwick BG -
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
J Clin Oncol Volume: 40 Page(s): 3057 - 3064
09/10/2022 Authors: Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S -
Smoldering multiple myeloma current treatment algorithms.
Blood Cancer J Volume: 12 Page(s): 129
09/05/2022 Authors: Rajkumar SV; Kumar S; Lonial S; Mateos MV -
adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma.
Haematologica Volume: 107 Page(s): 2226 - 2231
09/01/2022 Authors: Nair R; Subramaniam V; Barwick BG; Gupta VA; Matulis SM; Lonial S; Boise LH; Nooka AK; Muthumalaiappan K; Shanmugam M -
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
Blood Cancer J Volume: 12 Page(s): 115
08/04/2022 Authors: Gupta VA; Matulis SM; Barwick BG; Bog RD; Shebelut CW; Shanmugam M; Neri P; Bahlis NJ; Dhodapkar MV; Heffner LT -
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med Volume: 387 Page(s): 132 - 147
07/14/2022 Authors: Richardson PG; Jacobus SJ; Weller EA; Hassoun H; Lonial S; Raje NS; Medvedova E; McCarthy PL; Libby EN; Voorhees PM -
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
Blood Cancer Discov Volume: 3 Page(s): 273 - 284
07/06/2022 Authors: Davies FE; Pawlyn C; Usmani SZ; San-Miguel JF; Einsele H; Boyle EM; Corre J; Auclair D; Cho HJ; Lonial S -
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): 460 - 473
07/01/2022 Authors: Dimopoulos M-A; Richardson P; Lonial S -
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma.
Nat Commun Volume: 13 Page(s): 3750
06/29/2022 Authors: Vo JN; Wu Y-M; Mishler J; Hall S; Mannan R; Wang L; Ning Y; Zhou J; Hopkins AC; Estill JC -
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Lancet Haematol Volume: 9 Page(s): e403 - e414
06/01/2022 Authors: Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksa M; Legie W; Liberati AM; Goldschmidt H; Belch A -
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma.
Transplant Cell Ther Volume: 28 Page(s): 284 - 293
06/01/2022 Authors: Dhakal B; Shah N; Kansagra A; Kumar A; Lonial S; Garfall A; Cowan A; Poudyal BS; Costello C; Gay F -
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer.
Cell Volume: 185 Page(s): 1974 - 1985.e12
05/26/2022 Authors: Mo X; Niu Q; Ivanov AA; Tsang YH; Tang C; Shu C; Li Q; Qian K; Wahafu A; Doyle SP -
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Pharmacotherapy Volume: 42 Page(s): 233 - 240
03/01/2022 Authors: Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK -
Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting.
Life Sci Alliance Volume: 5
03/01/2022 Authors: Joyner CJ; Ley AM; Nguyen DC; Ali M; Corrado A; Tipton C; Scharer CD; Mi T; Woodruff MC; Hom J -
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.
Lancet Haematol Volume: 9 Page(s): e162 - e165
02/01/2022 Authors: Lonial S; Rajkumar SV; Mateos MV -
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
Lancet Haematol Volume: 9 Page(s): e143 - e161
02/01/2022 Authors: Raje NS; Anaissie E; Kumar SK; Lonial S; Martin T; Gertz MA; Krishnan A; Hari P; Ludwig H; O'Donnell E -
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life.
Transplant Cell Ther Volume: 28 Page(s): 75.e1 - 75.e7
02/01/2022 Authors: Joseph NS; Gupta VA; Wyman S; Graiser M; Kaufman JL; Almaula D; Andrews J; Hofmeister C; Dhodapkar M; Heffner LT -
"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma.
Cancer Volume: 127 Page(s): 4133 - 4136
11/15/2021 Authors: Nooka AK; Joseph NS; Lonial S -
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer Volume: 127 Page(s): 4198 - 4212
11/15/2021 Authors: Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah A-O; Callander N; Sborov D; Suvannasankha A -
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.
Blood Cancer Discov Volume: 2 Page(s): 600 - 615
11/01/2021 Authors: Kaushal A; Nooka AK; Carr AR; Pendleton KE; Barwick BG; Manalo J; McCachren SS; Gupta VA; Joseph NS; Hofmeister CC -
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Lancet Haematol Volume: 8 Page(s): e794 - e807
11/01/2021 Authors: Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A -
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
Clin Cancer Res Volume: 27 Page(s): 5195 - 5212
10/01/2021 Authors: Anderson KC; Auclair D; Adam SJ; Agarwal A; Anderson M; Avet-Loiseau H; Bustoros M; Chapman J; Connors DE; Dash A -
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 21 Page(s): 701 - 710
10/01/2021 Authors: Jakubowiak A; Usmani SZ; Krishnan A; Lonial S; Comenzo RL; Wang J; de Boer C; Deraedt W; Weiss BM; Schecter JM -
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.
Cancers (Basel) Volume: 13
09/24/2021 Authors: Ackley J; Ochoa MA; Ghoshal D; Roy K; Lonial S; Boise LH -
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells.
Mol Cell Volume: 81 Page(s): 3833 - 3847.e11
09/16/2021 Authors: Chen D; Xia S; Zhang R; Li Y; Famulare CA; Fan H; Wu R; Wang M; Zhu AC; Elf SE -
What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma.
J Clin Oncol Volume: 39 Page(s): 2423 - 2425
08/01/2021 Authors: D'Souza A; Lonial S -
Selinexor for the treatment of patients with previously treated multiple myeloma.
Expert Rev Hematol Volume: 14 Page(s): 697 - 706
08/01/2021 Authors: Mo CC; Jagannath S; Chari A; Nooka AK; Lonial S; Siegel D; Biran N; Gasparetto C; Bahlis NJ; Richardson P -
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood Volume: 137 Page(s): 3616 - 3628
07/01/2021 Authors: Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E -
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
Blood Volume: 137 Page(s): 3604 - 3615
07/01/2021 Authors: Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT -
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.
Clin Cancer Res Volume: 27 Page(s): 3178 - 3189
06/01/2021 Authors: Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC -
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
Blood Cancer J Volume: 11 Page(s): 103
05/26/2021 Authors: Lonial S; Nooka AK; Thulasi P; Badros AZ; Jeng BH; Callander NS; Potter HA; Sborov D; Zaugg BE; Popat R -
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
J Clin Oncol Volume: 39 Page(s): 1139 - 1149
04/01/2021 Authors: Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K -
An expanded universe of cancer targets.
Cell Volume: 184 Page(s): 1142 - 1155
03/04/2021 Authors: Hahn WC; Bader JS; Braun TP; Califano A; Clemons PA; Druker BJ; Ewald AJ; Fu H; Jagu S; Kemp CJ -
Antibody treatment in multiple myeloma.
Clin Adv Hematol Oncol Volume: 19 Page(s): 166 - 174
03/01/2021 Authors: Maples KT; Johnson C; Lonial S -
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Lancet Oncol Volume: 22 Page(s): e105 - e118
03/01/2021 Authors: Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F -
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
Am J Hematol Volume: 96 Page(s): E68 - E71
03/01/2021 Authors: Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH -
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype.
J Thorac Oncol Volume: 16 Page(s): 464 - 476
03/01/2021 Authors: Owonikoko TK; Dwivedi B; Chen Z; Zhang C; Barwick B; Ernani V; Zhang G; Gilbert-Ross M; Carlisle J; Khuri FR -
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med Volume: 384 Page(s): 705 - 716
02/25/2021 Authors: Munshi NC; Anderson LD; Shah N; Madduri D; Berdeja J; Lonial S; Raje N; Lin Y; Siegel D; Oriol A -
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma.
EJHaem Volume: 2 Page(s): 48 - 55
02/01/2021 Authors: Richardson PG; Jagannath S; Chari A; Vogl DT; Dimopoulos MA; Moreau P; Dingli D; Wei L-J; Richter J; Biran N -
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
Clin Pharmacol Volume: 13 Page(s): 169 - 180
01/01/2021 Authors: Joseph NS; Tai Y-T; Anderson KC; Lonial S -
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Lancet Oncol Volume: 22 Page(s): 142 - 154
01/01/2021 Authors: Laubach JP; Schjesvold F; Mariz M; Dimopoulos MA; Lech-Maranda E; Spicka I; Hungria VTM; Shelekhova T; Abdo A; Jacobasch L -
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Am J Hematol Volume: 96 Page(s): E5 - E8
01/01/2021 Authors: Cornell R; Hari P; Tang S; Biran N; Callander N; Chari A; Chhabra S; Fiala MA; Gahvari Z; Gandhi U -
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 21 Page(s): 46 - 54.e4
01/01/2021 Authors: Cohen YC; Oriol A; Wu KL; Lavi N; Vlummens P; Jackson C; Garvin W; Carson R; Crist W; Fu J -
Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
Blood Cancer J Volume: 10 Page(s): 125
12/14/2020 Authors: Gu Y; Barwick BG; Shanmugam M; Hofmeister CC; Kaufman J; Nooka A; Gupta V; Dhodapkar M; Boise LH; Lonial S -
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Ophthalmol Ther Volume: 9 Page(s): 889 - 911
12/01/2020 Authors: Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ -
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 797 - 803
12/01/2020 Authors: Kaufman JL; Mina R; Shah JJ; Laubach JP; Nooka AK; Lewis C; Gleason C; Sharp C; Harvey RD; Heffner LT -
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
Ophthalmol Ther Volume: 9 Page(s): 913 - 915
12/01/2020 Authors: Farooq AV; Degli Esposti S; Popat R; Thulasi P; Lonial S; Nooka AK; Jakubowiak A; Sborov D; Zaugg BE; Badros AZ -
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
J Clin Oncol Volume: 38 Page(s): 4030 - 4041
12/01/2020 Authors: Dimopoulos MA; pika I; Quach H; Oriol A; Hjek R; Garg M; Beksac M; Bringhen S; Katodritou E; Chng W-J -
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
J Immunother Cancer Volume: 8
12/01/2020 Authors: Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B -
We need CD38 STAT-JAK.
Blood Volume: 136 Page(s): 2246 - 2248
11/12/2020 Authors: Barwick BG; Lonial S -
Hitting a New Target in Multiple Myeloma.
Oncology (Williston Park) Volume: 34 Page(s): 488 - 489
11/12/2020 -
Practical approach to the management of smoldering myeloma.
Curr Opin Oncol Volume: 32 Page(s): 656 - 663
11/01/2020 Authors: Joseph NS; Lonial S -
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
Blood Cancer J Volume: 10 Page(s): 106
10/23/2020 Authors: Richardson PG; Lee HC; Abdallah A-O; Cohen AD; Kapoor P; Voorhees PM; Hoos A; Wang K; Baron J; Piontek T -
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol Volume: 21 Page(s): 1317 - 1330
10/01/2020 Authors: Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B -
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
Br J Cancer Volume: 123 Page(s): 1228 - 1234
10/01/2020 Authors: Harvey RD; Carthon BC; Lewis C; Hossain MS; Zhang C; Chen Z; Harris WB; Alese OB; Shaib W; Bilen MA -
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.
JCO Oncol Pract Volume: 16 Page(s): e1169 - e1180
10/01/2020 Authors: Yu Y; Brown Wade N; Hwang AE; Nooka AK; Fiala MA; Mohrbacher A; Peters ES; Pawlish K; Bock C; Van Den Berg DJ -
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
Blood Cancer J Volume: 10 Page(s): 91
09/04/2020 Authors: Dimopoulos MA; Lonial S; White D; Moreau P; Weisel K; San-Miguel J; Shpilberg O; Grosicki S; pika I; Walter-Croneck A -
Message from the Chairmen.
Clin Lymphoma Myeloma Leuk Volume: 20 Suppl 1 Page(s): S1
09/01/2020 Authors: Lonial S; Kantarjian H; Freireich EJ -
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Leukemia Volume: 34 Page(s): 2430 - 2440
09/01/2020 Authors: Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D -
Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes.
JCO Oncol Pract Volume: 16 Page(s): 431 - 434
08/01/2020 Authors: Cinar P; Cox J; Kamal A; Bickel K; Krzyzanowska M; Armitage J; Ganti AK; Ward J; Wong S; Lonial S -
Smoldering Myeloma and the Art of War.
J Clin Oncol Volume: 38 Page(s): 2363 - 2365
07/20/2020 Authors: Lonial S; Dhodapkar MV; Rajkumar SV -
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
Clin Cancer Res Volume: 26 Page(s): 3843 - 3855
07/15/2020 Authors: Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L -
Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IB degradation.
J Biol Chem Volume: 295 Page(s): 8869
06/26/2020 Authors: Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun S-Y -
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
J Clin Oncol Volume: 38 Page(s): 1928 - 1937
06/10/2020 Authors: Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK -
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
Lancet Haematol Volume: 7 Page(s): e447 - e455
06/01/2020 Authors: Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T -
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors.
Clin Cancer Res Volume: 26 Page(s): 2497 - 2505
06/01/2020 Authors: Owonikoko TK; Harvey RD; Carthon B; Chen Z; Lewis C; Collins H; Zhang C; Lawson DH; Alese OB; Bilen MA -
Reply to N. Biran et al.
J Clin Oncol Volume: 38 Page(s): 1368 - 1369
04/20/2020 Authors: Lonial S; Dhodapkar MV; Rajkumar SV -
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents.
Blood Cancer J Volume: 10 Page(s): 40
04/14/2020 Authors: Mina R; Joseph NS; Gay F; Kastritis E; Petrucci MT; Kaufman JL; Montefusco V; Gavriatopoulou M; Patriarca F; Omed P -
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
J Clin Oncol Volume: 38 Page(s): 1126 - 1137
04/10/2020 Authors: Lonial S; Jacobus S; Fonseca R; Weiss M; Kumar S; Orlowski RZ; Kaufman JL; Yacoub AM; Buadi FK; O'Brien T -
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Adv Ther Volume: 37 Page(s): 1464 - 1478
04/01/2020 Authors: Xu XS; Moreau P; Usmani SZ; Lonial S; Jakubowiak A; Oriol A; Krishnan A; Blad J; Luo M; Sun Y-N -
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
Nat Commun Volume: 11 Page(s): 1228
03/06/2020 Authors: Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A -
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol Volume: 21 Page(s): 207 - 221
02/01/2020 Authors: Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah A-O; Callander N; Lendvai N; Sborov D -
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
Blood Adv Volume: 4 Page(s): 181 - 190
01/14/2020 Authors: Du Z; Weinhold N; Song GC; Rand KA; Van Den Berg DJ; Hwang AE; Sheng X; Hom V; Ailawadhi S; Nooka AK -
-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A.
Mol Cell Volume: 76 Page(s): 857 - 871.e9
12/19/2019 Authors: Gao X; Zhao L; Liu S; Li Y; Xia S; Chen D; Wang M; Wu S; Dai Q; Vu H -
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Blood Cancer J Volume: 9 Page(s): 94
11/25/2019 Authors: Schmidt TM; Barwick BG; Joseph N; Heffner LT; Hofmeister CC; Bernal L; Dhodapkar MV; Gupta VA; Jaye DL; Wu J -
Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM)
Volume: 19 Page(s): E115 - E116
10/01/2019 Authors: Cornell R; Parameswaran H; Tang S; Barnstead A; Biran N; Callander N; Chari A; Chhabra S; Fiala M; Gahvari Z -
Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study
Volume: 19 Page(s): E118 - E119
10/01/2019 Authors: Vogl DT; Nooka A; Gavriatopoulou M; Yee A; Huff C; Moreau P; Dingli D; Cole C; Richardson PG; Dimopoulos MA -
Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study
Volume: 19 Page(s): E117 - E118
10/01/2019 Authors: Gavriatopoulou M; Vogl DT; Nooka A; Dingli D; Cole C; Moreau P; Huff C; Yee A; Dimopoulos MA; Lonial S -
A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Volume: 19 Page(s): E52 - E53
10/01/2019 Authors: Lonial S; Van de Donk N; Popat R; Zonder JA; Minnema M; Larsen JT; Tuong VN; Chen MS; Bensmaine A; Peluso T -
Identification and Molecular Characterization of High-Risk Multiple Myeloma Patients from the MMRF CoMMpass Study at Diagnosis and Progression
Volume: 19 Page(s): E7 - E7
10/01/2019 Authors: Skerget S; Christofferson A; Nasser S; Legendre C; Yesil J; Auclair D; Lonial S; Keats J -
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
Volume: 19 Page(s): E15 - E16
10/01/2019 Authors: Dimopoulos MA; Weisel K; Lonial S; White D; Moreau P; Mateos M-V; San-Miguel J; Anderson KC; Shpilberg O; Grosicki S -
DNA methylation reprogramming in relapsed/refractory myeloma converges with loci prognostic of survival in newly diagnosed patients
Volume: 19 Page(s): E57 - E57
10/01/2019 Authors: Barwick B; Skerget S; Keats J; Auclair D; Lonial S; Boise L; Vertino P -
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Volume: 19 Page(s): E243 - E244
10/01/2019 Authors: Bernal L; Nooka A; Cole C; Heffner LT; Ye JC; Vij R; Chen Z; Zhang C; Rushton J; Munevver C -
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation.
J Clin Invest Volume: 129 Page(s): 4110 - 4123
10/01/2019 Authors: Pan C; Chun J; Li D; Boese AC; Li J; Kang J; Umano A; Jiang Y; Song L; Magliocca KR -
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Volume: 125 Page(s): 2991 - 3000
09/01/2019 Authors: Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S -
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 537 - 544
09/01/2019 Authors: Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ -
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
Lancet Haematol Volume: 6 Page(s): e448 - e458
09/01/2019 Authors: Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD -
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Lancet Haematol Volume: 6 Page(s): e459 - e469
09/01/2019 Authors: Mateos M-V; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D -
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med Volume: 381 Page(s): 727 - 738
08/22/2019 Authors: Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S -
Is there still a role for stem cell transplantation in multiple myeloma?
Cancer Volume: 125 Page(s): 2534 - 2543
08/01/2019 Authors: Mina R; Lonial S -
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Blood Volume: 134 Page(s): 421 - 431
08/01/2019 Authors: Chari A; Martinez-Lopez J; Mateos M-V; Blad J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A -
Daratumumab in multiple myeloma.
Cancer Volume: 125 Page(s): 2364 - 2382
07/15/2019 Authors: Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S -
Registering a CD38 antibody upfront for multiple myeloma.
Lancet Volume: 394 Page(s): 3 - 4
07/06/2019 Authors: Hofmeister CC; Nooka A; Kaufman JL; Lonial S -
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Leukemia Volume: 33 Page(s): 1736 - 1746
07/01/2019 Authors: Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R -
Deciphering a metabolic basis for single-agent venetoclax efficacy in t(11;14) multiple myeloma
Volume: 79
07/01/2019 Authors: Bajpai R; Achreja A; Wei C; Siddiqa A; Matulis SM; Gupta V; McBrayer SK; Mittal A; Rupji M; Chen H-R -
Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma
Volume: 79
07/01/2019 Authors: Joseph N; Gupta VA; Hofmeister C; Gleason C; Heffner LT; Jonathan KL; Boise LH; Dhodapkar MD; Lonial S; Nooka AK -
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies.
Cancer Volume: 125 Page(s): 2322 - 2324
07/01/2019 Authors: Harvey RD; Zhang C; Lonial S; Kaufman JL; Chen Z -
Whole genome DNA methylation analysis of multiple myeloma identifies pervasive hypomethylation and biomarkers of survival
Volume: 79
07/01/2019 Authors: Barwick BG; Powell DR; Penaherrera D; Skerget S; Keats JJ; Auclair D; Lonial S; Boise LH; Vertino PM -
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Cancer Discov Volume: 9 Page(s): 756 - 777
06/01/2019 Authors: Chen D; Xia S; Wang M; Lin R; Li Y; Mao H; Aguiar M; Famulare CA; Shih AH; Brennan CW -
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 372 - 380
06/01/2019 Authors: Jagannath S; Heffner LT; Ailawadhi S; Munshi NC; Zimmerman TM; Rosenblatt J; Lonial S; Chanan-Khan A; Ruehle M; Rharbaoui F -
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): 332 - 344
06/01/2019 Authors: Ghobrial I; Cruz CH; Garfall A; Shah N; Munshi N; Kaufman J; Boise LH; Morgan G; Adalsteinsson VA; Manier S -
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
Lancet Oncol Volume: 20 Page(s): e302 - e312
06/01/2019 Authors: Hillengass J; Usmani S; Rajkumar SV; Durie BGM; Mateos M-V; Lonial S; Joao C; Anderson KC; Garca-Sanz R; Riva E -
A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC).
Volume: 37
05/20/2019 Authors: Owonikoko TK; Higgins KA; Chen Z; Zhang C; Pillai RN; Steuer CE; Saba NF; Pakkala S; Shin DM; Zhang G -
ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status.
Volume: 37
05/20/2019 Authors: Thompson MA; Jacobus SJ; Kumar S; Janakiram M; Lonial S; Weiss M; Callander NS; Rajkumar SV -
Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance.
J Clin Invest Volume: 129 Page(s): 2431 - 2445
05/13/2019 Authors: Pan C; Jin L; Wang X; Li Y; Chun J; Boese AC; Li D; Kang H-B; Zhang G; Zhou L -
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
Leukemia Volume: 33 Page(s): 1291 - 1296
05/01/2019 Authors: Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL -
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Nat Commun Volume: 10 Page(s): 1911
04/23/2019 Authors: Barwick BG; Neri P; Bahlis NJ; Nooka AK; Dhodapkar MV; Jaye DL; Hofmeister CC; Kaufman JL; Gupta VA; Auclair D -
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.
JCI Insight Volume: 5
04/23/2019 Authors: Bailur JK; McCachren SS; Doxie DB; Shrestha M; Pendleton K; Nooka AK; Neparidze N; Parker TL; Bar N; Kaufman JL -
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Cytometry A Volume: 95 Page(s): 279 - 289
03/01/2019 Authors: Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G -
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
Br J Haematol Volume: 184 Page(s): 475 - 479
02/01/2019 Authors: van de Donk NWCJ; Casneuf T; Di Cara A; Parren PW; Zweegman S; van Kessel B; Lokhorst HM; Usmani SZ; Lonial S; Richardson PG -
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Cancer Volume: 125 Page(s): 416 - 423
02/01/2019 Authors: Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK -
Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Cancer Volume: 125 Page(s): 185 - 193
01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR -
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.
Blood Cancer J Volume: 9 Page(s): 3
01/04/2019 Authors: Kaufman JL; Mina R; Jakubowiak AJ; Zimmerman TL; Wolf JJ; Lewis C; Gleason C; Sharp C; Martin T; Heffner LT -
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
Leukemia Volume: 33 Page(s): 159 - 170
01/01/2019 Authors: Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies F; Rosenthal A; Wang H; Qu P; Hoering A -
Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
PLoS One Volume: 14 Page(s): e0206309
01/01/2019 Authors: Owonikoko TK; Zhang G; Lallani SB; Chen Z; Martinson DE; Khuri FR; Lonial S; Marcus A; Sun S-Y -
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma.
Cancer J Volume: 25 Page(s): 19 - 31
01/01/2019 Authors: Nooka AK; Lonial S -
Ixazomib for the treatment of multiple myeloma.
Expert Opin Pharmacother Volume: 19 Page(s): 1949 - 1968
12/01/2018 Authors: Richardson PG; Zweegman S; O'Donnell EK; Laubach JP; Raje N; Voorhees P; Ferrari RH; Skacel T; Kumar SK; Lonial S -
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.
Future Oncol Volume: 14 Page(s): 3111 - 3121
12/01/2018 Authors: Chehab S; Panjic EH; Gleason C; Lonial S; Nooka AK -
An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma
Volume: 132
11/29/2018 Authors: Nasser S; Aldrich J; Penaherrera D; Christofferson A; Legendre C; Yesil J; Auclair D; Liang W; Lonial S; Skerget S -
Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis
Volume: 132
11/29/2018 Authors: Penaherrera D; Skerget S; Christofferson A; Aldrich J; Nasser S; Legendre C; Boateng M; Cuyugan L; Adkins J; Tassone E -
Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype
Volume: 132
11/29/2018 Authors: Skerget S; Penaherrera D; Aldrich J; Nasser S; Christofferson A; Legendre C; Boateng M; Cuyugan L; Adkins J; Tassone E -
Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses
Volume: 132
11/29/2018 Authors: Xu XS; Moreau P; Usmani SZ; Lonial S; Jakubowiak A; Oriol A; Krishnan A; Blade J; Luo M; Sun Y-N -
A Role for Syntenin-1 in Multiple Myeloma Cell Survival
Volume: 132
11/29/2018 Authors: Moser-Katz T; Gavile CM; Barwick BG; Lonial S; Boise LH -
Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function
Volume: 132
11/29/2018 Authors: Chen B; Pamela W; Auclair D; Keats JJ; Secrist P; Cidado J; Tron AE; Dunham CM; Lonial S; Opferman J -
Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy
Volume: 132
11/29/2018 Authors: Barwick BG; Neri P; Bahlis N; Nooka AK; Kaufman JL; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM -
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Cancer Volume: 124 Page(s): 4342 - 4349
11/15/2018 Authors: Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B -
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.
Cancer Volume: 124 Page(s): 4358 - 4365
11/15/2018 Authors: Chehab S; Zhang C; Panjic EH; Chen Z; Kaufman JL; Lonial S; Nooka A; Harvey RD -
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.
Cancer Lett Volume: 435 Page(s): 44 - 54
10/28/2018 Authors: Qian G; Yao W; Zhang S; Bajpai R; Hall WD; Shanmugam M; Lonial S; Sun S-Y -
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Cancer Volume: 124 Page(s): 4032 - 4043
10/15/2018 Authors: Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O -
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Leukemia Volume: 32 Page(s): 2305
10/01/2018 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J -
Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High-risk Population
Volume: 18 Page(s): S250 - S251
09/01/2018 Authors: Schmidt T; Mina R; Joseph N; Gay F; Nooka A; Kastritis E; Spada S; Kaufman J; Montefusco V; Gilestro M -
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
Volume: 18 Page(s): S253 - S253
09/01/2018 Authors: Lonial S; Dimopoulos M; Weisel K; White D; Moreau P; Mateos M-V; San Miguel J; Anderson K; Shpilberg O; Grosicki S -
Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM)
Volume: 18 Page(s): S248 - S249
09/01/2018 Authors: Lonial S; Chng WJ; Beksac M; Hajek R; Weisel K; Mateos M-V; Spencer A; Iida S; de Farias D; Labotka R -
How Does Genetics and MRD Impact Treatment or Doesn't It?
Volume: 18 Page(s): S69 - S72
09/01/2018 Authors: Nooka AK; Lonial S -
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma.
J Oncol Pract Volume: 14 Page(s): 561 - 564
09/01/2018 Authors: Chang A; Nasti TH; Khan MK; Parashar S; Kaufman JL; Boise LH; Lonial S; Ahmed R; Nooka AK -
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
Haematologica Volume: 103 Page(s): 1518 - 1526
09/01/2018 Authors: San-Miguel JF; Echeveste Gutierrez M-A; picka I; Mateos M-V; Song K; Craig MD; Blad J; Hjek R; Chen C; Di Bacco A -
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study.
Blood Cancer J Volume: 8 Page(s): 86
08/29/2018 Authors: Mikhael J; Manola J; Dueck AC; Hayman S; Oettel K; Kanate AS; Lonial S; Rajkumar SV -
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation.
Cancer Cell Volume: 34 Page(s): 315 - 330.e7
08/13/2018 Authors: Jin L; Chun J; Pan C; Li D; Lin R; Alesi GN; Wang X; Kang H-B; Song L; Wang D -
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Blood Volume: 132 Page(s): 587 - 597
08/09/2018 Authors: Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies FE; Rosenthal A; Wang H; Qu P; Hoering A -
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.
J Oncol Pract Volume: 14 Page(s): 414 - 422
07/01/2018 Authors: Nooka AK; Gleason C; Sargeant MO; Walker M; Watson M; Panjic EH; Lonial S -
A meta-analysis of genome-wide association studies of multiple myeloma among African Americans
Volume: 78
07/01/2018 Authors: Du Z; Song C; Rand K; Weinhold N; Van den Berg D; Hwang A; Sheng X; Hom V; Ailawadhi S; Nooka AK -
Syntenin regulates multiple myeloma cell survival
Volume: 78
07/01/2018 Authors: Moser-Katz T; Gavile CM; Barwick BG; Lonial S; Boise LH -
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy
Volume: 78
07/01/2018 Authors: Qian G; Yao W; Hall WD; Shanmugam M; Lonial S; Sun S-Y -
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after 2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.
Br J Haematol Volume: 181 Page(s): 628 - 636
06/01/2018 Authors: Richardson PG; Schlossman RL; Roy AN; Panneerselvam A; Acharyya S; Sopala M; Lonial S -
Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM).
Volume: 36
05/20/2018 Authors: Chng WJ; Beksac M; Hajek R; Weisel K; Mateos M-V; Spencer A; Iida S; de Farias D; Labotka R; Skacel T -
Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction.
Volume: 36
05/20/2018 Authors: Harvey RD; Kaufman JL; Heffner LT; Hofmeister CC; Dhodapkar MV; Lonial S; Nooka AK -
Current developments in immunotherapy in the treatment of multiple myeloma.
Cancer Volume: 124 Page(s): 2075 - 2085
05/15/2018 Authors: Khler M; Greil C; Hudecek M; Lonial S; Raje N; Wsch R; Engelhardt M -
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
Clin Pharmacokinet Volume: 57 Page(s): 529 - 538
04/01/2018 Authors: Yan X; Clemens PL; Puchalski T; Lonial S; Lokhorst H; Voorhees PM; Usmani S; Richardson PG; Plesner T; Liu K -
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Mol Cell Volume: 69 Page(s): 923 - 937.e8
03/15/2018 Authors: Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang H-B; Pan Y; Liu S -
14-3-3 binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors.
Leukemia Volume: 32 Page(s): 744 - 751
03/01/2018 Authors: Gu Y; Xu K; Torre C; Samur M; Barwick BG; Rupji M; Arora J; Neri P; Kaufman J; Nooka A -
Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT)
Volume: 24 Page(s): S135 - S136
03/01/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff J; Gupta V; Lechowicz M; Al-Kadhimi Z; Nooka A; Kaufman J; Lonial S -
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Leukemia
02/23/2018 Authors: Krishnan A; Kapoor P; Palmer JM; Tsai N-C; Kumar S; Lonial S; Htut M; Karanes C; Nathwani N; Rosenzweig M -
Phase 3 ELOQUENT-2 study extended 5-y follow-up comparing elotuzumab plus lenalidomide/dexamethasone (ELd) with Ld to treat relapsed/refractory multiple myeloma
Volume: 41 Page(s): 230 - 230
01/01/2018 Authors: Weisel K; Dimopoulos MA; Lonial S; White D; Moreau P; Mateos M; San Miguel J; Anderson K; Shpilberg O; Grosicki S -
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma.
Leukemia Volume: 32 Page(s): 120 - 130
01/01/2018 Authors: Lagan A; Perumal D; Melnekoff D; Readhead B; Kidd BA; Leshchenko V; Kuo P-Y; Keats J; DeRome M; Yesil J -
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
Leukemia
12/18/2017 Authors: Krishnan A; Kapoor P; Palmer JM; Tsai N-C; Kumar S; Lonial S; Htut M; Karanes C; Nathwani N; Rosenzweig M -
Succinate Ubiquinone Reductase Activity Predicts Multiple Myeloma Sensitivity to Venetoclax
Volume: 130
12/07/2017 Authors: Bajpai R; Wei C; Matulis S; Nooka AK; McBrayer S; Lonial S; Gupta VA; Boise LH; Shanmugam M -
High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations
Volume: 130
12/07/2017 Authors: Barwick B; Gupta VA; Auclair D; Keats JJ; Lonial S; Vertino PM; Boise LH -
A Meta-Analysis of Genome-Wide Association Studies of Multiple Myeloma in Persons of African Ancestry [African-American Multiple Myeloma Study (AAMMS)] Identifies Suggestive Risk Variants
Volume: 130
12/07/2017 Authors: Du Z; Weinhold N; Van den Berg D; Hwang A; Sheng X; Hom V; Ailawadhi S; Nooka AK; Singhal S; Pawlish K -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
Volume: 130
12/07/2017 Authors: Joseph N; Almaula D; Gleason C; Heffner L; Boise LH; Kaufman JL; Lonial S; Nooka A -
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.
Leukemia Volume: 31 Page(s): 2695 - 2701
12/01/2017 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J -
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Cancer Volume: 123 Page(s): 4617 - 4630
12/01/2017 Authors: Shah JJ; Kaufman JL; Zonder JA; Cohen AD; Bensinger WI; Hilder BW; Rush SA; Walker DH; Tunquist BJ; Litwiler KS -
CD86 regulates myeloma cell survival.
Blood Adv Volume: 1 Page(s): 2307 - 2319
11/28/2017 Authors: Gavile CM; Barwick BG; Newman S; Neri P; Nooka AK; Lonial S; Lee KP; Boise LH -
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
Blood Adv Volume: 1 Page(s): 2105 - 2114
10/24/2017 Authors: Casneuf T; Xu XS; Adams HC; Axel AE; Chiu C; Khan I; Ahmadi T; Yan X; Lonial S; Plesner T -
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
Br J Haematol Volume: 179 Page(s): 66 - 74
10/01/2017 Authors: San-Miguel JF; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Na Nakorn T; Siritanaratkul N -
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Expert Rev Hematol Volume: 10 Page(s): 933 - 939
10/01/2017 Authors: Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Gnther A; Lonial S; Einsele H -
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma.
Blood Adv Volume: 1 Page(s): 1848 - 1853
09/26/2017 Authors: Shah SP; Nooka AK; Lonial S; Boise LH -
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.
Blood Cancer J Volume: 7 Page(s): e612
09/22/2017 Authors: Miller A; Asmann Y; Cattaneo L; Braggio E; Keats J; Auclair D; Lonial S; MMRF CoMMpass Network; Russell SJ; Stewart AK -
Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM)
Volume: 28
09/01/2017 Authors: Usmani SZ; Jakubowiak A; Chari A; Lonial S; Mateos M-V; Benboubker L; Wu K; Khokhar NZ; Wang J; Doshi P -
Phase 3 ELOQUENT-2 study: extended 4-year follow-up of Elotuzumab plus lenalidomide/ dexamethasone vs lenalidomide/ dexamethasone in relapsed/ refractory multiple myeloma
Volume: 40 Page(s): 35 - 35
09/01/2017 Authors: Weisel K; Dimopoulos MA; Lonial S; White D; Moreau P; Mateos M-V; San Miguel J; Anderson KC; Shpilberg O; Grosicki S -
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Br J Haematol Volume: 178 Page(s): 896 - 905
09/01/2017 Authors: Dimopoulos MA; Lonial S; White D; Moreau P; Palumbo A; San-Miguel J; Shpilberg O; Anderson K; Grosicki S; Spicka I -
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): 555 - 562
09/01/2017 Authors: van Beers EH; van Vliet MH; Kuiper R; de Best L; Anderson KC; Chari A; Jagannath S; Jakubowiak A; Kumar SK; Levy JB -
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Blood Volume: 130 Page(s): 974 - 981
08/24/2017 Authors: Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R -
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
Clin Pharmacokinet Volume: 56 Page(s): 915 - 924
08/01/2017 Authors: Clemens PL; Yan X; Lokhorst HM; Lonial S; Losic N; Khan I; Jansson R; Ahmadi T; Lantz K; Zhou H -
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.
Br J Haematol Volume: 178 Page(s): 547 - 560
08/01/2017 Authors: Laubach JP; Moslehi JJ; Francis SA; San Miguel JF; Sonneveld P; Orlowski RZ; Moreau P; Rosiol L; Faber EA; Voorhees P -
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Br J Haematol Volume: 178 Page(s): 571 - 582
08/01/2017 Authors: Kumar S; Moreau P; Hari P; Mateos M-V; Ludwig H; Shustik C; Masszi T; Spencer A; Hjek R; Romeril K -
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Clin Cancer Res Volume: 23 Page(s): 3307 - 3315
07/01/2017 Authors: Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS -
High-risk Multiple Myeloma: Definition and Management.
Clin Lymphoma Myeloma Leuk Volume: 17S Page(s): S80 - S87
07/01/2017 Authors: Joseph NS; Gentili S; Kaufman JL; Lonial S; Nooka AK -
PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Volume: 102 Page(s): 167 - 168
06/26/2017 Authors: Dimopoulos MA; Lonial S; White D; Moreau P; Mateos M-V; San Miguel J; Anderson KC; Shpilberg O; Grosicki S; Spicka I -
AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
Volume: 102 Page(s): 269 - 269
06/26/2017 Authors: Usmani SZ; Chari A; Lonial S; Weiss B; Comenzo RL; Wu K; Khokhar NZ; Wang J; Doshi P; Jakubowiak A -
DEEP AND DURABLE RESPONSES WITH WEEKLY IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS WHO DID NOT UNDERGO SCT
Volume: 102 Page(s): 142 - +
06/26/2017 Authors: Kumar S; Berdeja J; Niesvizky R; Lonial S; Laubach J; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R -
HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.
J Biol Chem Volume: 292 Page(s): 10142 - 10152
06/16/2017 Authors: Zhao L; Fan J; Xia S; Pan Y; Liu S; Qian G; Qian Z; Kang H-B; Arbiser JL; Pollack BP -
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.
Volume: 129 Page(s): 3033 - 3037
06/01/2017 Authors: Sullivan HC; Gerner-Smidt C; Nooka AK; Arthur CM; Thompson L; Mener A; Patel SR; Yee M; Fasano RM; Josephson CD -
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.
Clin Pharmacol Ther Volume: 101 Page(s): 721 - 724
06/01/2017 Authors: Xu XS; Yan X; Puchalski T; Lonial S; Lokhorst HM; Voorhees PM; Plesner T; Liu K; Khan I; Jansson R -
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study.
Infect Control Hosp Epidemiol Volume: 38 Page(s): 651 - 657
06/01/2017 Authors: Shah NN; McClellan W; Flowers CR; Lonial S; Khoury H; Waller EK; Langston A; Nooka AK -
Academic, Foundation, and Industry Collaboration in Finding New Therapies.
N Engl J Med Volume: 376 Page(s): 1762 - 1769
05/04/2017 Authors: Ramsey BW; Nepom GT; Lonial S -
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Blood Volume: 129 Page(s): 1969 - 1979
04/06/2017 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.
Lancet Oncol Volume: 18 Page(s): e206 - e217
04/01/2017 Authors: Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH -
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma.
Nucleic Acids Res Volume: 45 Page(s): 2396 - 2407
03/17/2017 Authors: Wang D; Hashimoto H; Zhang X; Barwick BG; Lonial S; Boise LH; Vertino PM; Cheng X -
Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma.
Pharmacol Res Volume: 117 Page(s): 185 - 191
03/01/2017 Authors: Richardson PG; Moreau P; Laubach JP; Maglio ME; Lonial S; San-Miguel J -
Deacetylase inhibitors: an advance in myeloma therapy?
Expert Rev Hematol Volume: 10 Page(s): 229 - 237
03/01/2017 Authors: Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG -
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth.
Cell Metab Volume: 25 Page(s): 358 - 373
02/07/2017 Authors: Xia S; Lin R; Jin L; Zhao L; Kang H-B; Pan Y; Liu S; Qian G; Qian Z; Konstantakou E -
Safety of proteasome inhibitors for treatment of multiple myeloma.
Expert Opin Drug Saf Volume: 16 Page(s): 167 - 183
02/01/2017 Authors: Schlafer D; Shah KS; Panjic EH; Lonial S -
Insights Into the Appropriate Use of New Antimyeloma Therapies.
Oncology (Williston Park) Volume: 31 Page(s): 64 - 66
01/15/2017 Authors: Kaufman JL; Lonial S -
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin.
Oncogene Volume: 36 Page(s): 254 - 262
01/12/2017 Authors: Elf S; Lin R; Xia S; Pan Y; Shan C; Wu S; Lonial S; Gaddh M; Arellano ML; Khoury HJ -
How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma.
J Clin Oncol Volume: 34 Page(s): 4421 - 4430
12/20/2016 Authors: Hofmeister CC; Lonial S -
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
Clin Cancer Res Volume: 22 Page(s): 5959 - 5965
12/15/2016 Authors: Neri P; Bahlis NJ; Lonial S -
Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant
Volume: 128
12/02/2016 Authors: Kumar P; Joseph N; Almaula D; Boise LH; Kaufman JL; Gleason C; Lonial S; Nooka AK -
Areas of Consensus and Differences Among a Panel of Experts on the Optimal Use of Newly Approved Agents to Treat Multiple Myeloma (MM): Results from an Annually Updated Online Decision Support Tool
Volume: 128
12/02/2016 Authors: Quill TA; Rosenthal KM; Kumar S; Lentzsch S; Lonial S; Roodman GD; Obholz KL; Anderson KC -
Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response
Volume: 128
12/02/2016 Authors: Gruber F; Keats JJ; McBride K; Runge K; Wuest D; Hadzi T; Derome M; Lonial S; Khalil I; Hayete B -
Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study
Volume: 128
12/02/2016 Authors: Mikhael J; Manola J; Lonial S; Weiss BM; Oettel K; Hayman SR; Kanate AS; Rajkumar SV -
HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)
Volume: 128
12/02/2016 Authors: Gragert L; Hwang A; Bernal-Mizrachi L; Ailawadhi S; Singhal S; Vandenberg DJ; Sheng X; Stram A; Conti DV; Rand KA -
B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma
Volume: 128
12/02/2016 Authors: Gupta VA; Newman S; Bahlis NJ; Keats JJ; Matulis S; Rossi MR; Auclair D; Nooka AK; Kaufman JL; Lonial S -
Final Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
Volume: 128
12/02/2016 Authors: Nooka AK; Wang M; Yee AJ; Thomas SK; O'Donnell EK; Shah JJ; Kaufman JL; Peterkin D; Lonial S; Richardson PG -
A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics
Volume: 128
12/02/2016 Authors: Krishnan A; Kapoor P; Palmer J; Tsai N-C; Kumar S; Lonial S; Htut M; Karanes C; Nathwani N; Rosenzweig M -
Correlation Between Somatic Mutation Burden, Neoantigen Load and Progression Free Survival in Multiple Myeloma: Analysis of MMRF CoMMpass Study
Volume: 128
12/02/2016 Authors: Miller A; Cattaneo L; Asmann YW; Braggio E; Keats JJ; Auclair D; Lonial S; Russell SJ; Stewart AK -
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth.
Mol Cell Volume: 64 Page(s): 859 - 874
12/01/2016 Authors: Fan J; Lin R; Xia S; Chen D; Elf SE; Liu S; Pan Y; Xu H; Qian Z; Wang M -
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
Cancer Epidemiol Biomarkers Prev Volume: 25 Page(s): 1609 - 1618
12/01/2016 Authors: Rand KA; Song C; Dean E; Serie DJ; Curtin K; Sheng X; Hu D; Huff CA; Bernal-Mizrachi L; Tomasson MH -
Integration of Novel Agents into the Care of Patients with Multiple Myeloma.
Clin Cancer Res Volume: 22 Page(s): 5443 - 5452
11/15/2016 Authors: Orlowski RZ; Lonial S -
KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Volume: 27
11/01/2016 Authors: Mateos MV; Blacklock H; Rocafiguera AO; Iida S; Jagannath S; Lonial S; Kher U; Farooqui M; Marinello P; San-Miguel J -
KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)
Volume: 27
11/01/2016 Authors: Lonial S; de Oliveira MR; Yimer H; Mateos MV; Rifkin R; Schjesvold F; San-Miguel J; Ghori R; Marinello P; Jagannath S -
HLA polymorphism and risk of multiple myeloma.
Leukemia Volume: 30 Page(s): 2260 - 2264
11/01/2016 Authors: Beksac M; Gragert L; Fingerson S; Maiers M; Zhang M-J; Albrecht M; Zhong X; Cozen W; Dispenzieri A; Lonial S -
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
Lancet Haematol Volume: 3 Page(s): e506 - e515
11/01/2016 Authors: San-Miguel JF; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Gnther A; Nakorn TN; Siritanaratkul N -
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation.
Cancer Volume: 122 Page(s): 3207 - 3214
10/15/2016 Authors: Nooka AK; Behera M; Lonial S; Dixon MD; Ramalingam SS; Pentz RD -
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
Expert Opin Biol Ther Volume: 16 Page(s): 1291 - 1301
10/01/2016 Authors: Lonial S; Kaufman J; Reece D; Mateos M-V; Laubach J; Richardson P -
Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Drugs Today (Barc) Volume: 52 Page(s): 551 - 560
10/01/2016 Authors: Xia C; Ribeiro M; Scott S; Lonial S -
Elotuzumab plus lenalidomide and dexamethasone (ELd) in relapsed/refractory multiple myeloma (RRMM): ELOQUENT-2 post-hoc analysis of progression-free survival (PFS), tumor regrowth by time from diagnosis and prior lines of therapy, and median duration of response (DOR)
Volume: 39 Page(s): 223 - 223
10/01/2016 Authors: Weisel K; Dimopoulos MA; Palumbo A; Richardson P; Mateos M; Moreau P; Gupta M; Sheng J; Passey C; Sy O -
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation.
Oncotarget Volume: 7 Page(s): 59727 - 59741
09/13/2016 Authors: Shah SP; Nooka AK; Jaye DL; Bahlis NJ; Lonial S; Boise LH -
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Clin Lymphoma Myeloma Leuk Volume: 16 Page(s): 466 - 471.e1
08/01/2016 Authors: DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R -
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Lancet Oncol Volume: 17 Page(s): e328 - e346
08/01/2016 Authors: Kumar S; Paiva B; Anderson KC; Durie B; Landgren O; Moreau P; Munshi N; Lonial S; Blad J; Mateos M-V -
Is Maintenance Therapy for Everyone?
Clin Lymphoma Myeloma Leuk Volume: 16 Suppl Page(s): S139 - S144
08/01/2016 Authors: Nooka AK; Lonial S -
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
Oncogene Volume: 35 Page(s): 3955 - 3964
07/28/2016 Authors: Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M -
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Volume: 128 Page(s): 37 - 44
07/07/2016 Authors: Usmani SZ; Weiss BM; Plesner T; Bahlis NJ; Belch A; Lonial S; Lokhorst HM; Voorhees PM; Richardson PG; Chari A -
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma.
Volume: 17 Page(s): 769 - 777
07/02/2016 Authors: Ponder KG; Matulis SM; Hitosugi S; Gupta VA; Sharp C; Burrows F; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Death by a thousand cuts: the slow demise of chemotherapy.
Cancer Volume: 122 Page(s): 1971 - 1973
07/01/2016 Authors: Nooka AK; Lonial S -
Lack of health maintenance examinations and risk in myeloma patients.
Cancer Med Volume: 5 Page(s): 1425 - 1435
07/01/2016 Authors: Tariman JD; Gleason C; Faiman B; Doss D; Catamero D; Bishop-Royse J; Katz M; Kurtin S; Moran D; IMF Nurse Leadership Board -
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Blood Volume: 127 Page(s): 2955 - 2962
06/16/2016 Authors: Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng W-J; Moreau P; Attal M; Kyle RA -
ELOTUZUMAB plus LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: ELOQUENT-2 POST-HOC ANALYSIS OF PFS AND TUMOR REGROWTH BY TIME FROM DIAGNOSIS AND PRIOR LINES OF THERAPY
Volume: 101 Page(s): 85 - 85
06/01/2016 Authors: Dimopoulos MA; Palumbo A; Weisel K; Richardson P; Mateos MV; Moreau P; Gupta M; Sheng J; Passey C; Sy O -
PATIENT REPORTED OUTCOMES (PROS) OF MULTIPLE MYELOMA (MM) PATIENTS FROM THE PANORAMA-1 STUDY WHO HAVE RECEIVED AT LEAST TWO PRIOR REGIMENS INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT
Volume: 101 Page(s): 786 - 786
06/01/2016 Authors: Richardson PG; Hungria V; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Jedrzejczak WW; Nakorn TN; Siritanaratkul N -
PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Volume: 101 Page(s): 87 - 88
06/01/2016 Authors: Casneuf T; Xu XS; Adams H; Axel A; Verbist B; Liu K; Khan I; Ahmadi T; Yan X; Lonial S -
RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HDAC6 INHIBITOR, COMBINED WITH POMALIDOMIDE AND DEXAMETHASONE SHOWS PROMISING EARLY PHASE 2 RESULTS IN RELAPSED-AND-REFRACTORY MULTIPLE MYELOMA: ACE-MM-102
Volume: 101 Page(s): 328 - 328
06/01/2016 Authors: Raje N; Terpos E; Cole C; Bahlis N; Bensinger W; Libby E; Palumbo A; Lonial S; Sandhu I; Arce-Lara C -
POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE IN PROTEASOME INHIBITOR-EXPOSED AND LENALIDOMIDE-REFRACTORY MYELOMA: RESULTS OF A MULTICENTER, DOSE-ESCALATION, PHASE 1 TRIAL (MM-005)
Volume: 101 Page(s): 257 - 257
06/01/2016 Authors: Richardson PG; Hofmeister CC; Raje NS; Siegel DS; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J -
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Am J Hematol Volume: 91 Page(s): 575 - 580
06/01/2016 Authors: Jurczyszyn A; Grzasko N; Gozzetti A; Czepiel J; Cerase A; Hungria V; Crusoe E; Silva Dias ALM; Vij R; Fiala MA -
Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: Meta-analysis of phase 3 randomized controlled trials.
Volume: 34
05/20/2016 Authors: Nooka AK; Kaufman JL; Lonial S -
Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after?2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial.
Volume: 34
05/20/2016 Authors: Richardson PG; Lonial S; Schlossman RL; Roy AN; Majer I; Panneerselvam A; Sopala M; Miguel JS -
Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and-MM4.
Volume: 34
05/20/2016 Authors: Palumbo A; Morgan GJ; Rajkumar SV; Lonial S; Chng WJ; Iida S; Mateos M-V; Beksac M; Goldschmidt H; Labotka R -
A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
Volume: 34
05/20/2016 Authors: San Miguel J; Raab MS; Goldschmidt H; Lonial S; Richardson PG; Shelat S; Bleickardt EW; Palumbo A -
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth.
Oncotarget Volume: 7 Page(s): 27753 - 27763
05/10/2016 Authors: Deng J; Park D; Wang M; Nooka A; Deng Q; Matulis S; Kaufman J; Lonial S; Boise LH; Galipeau J -
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
Leukemia Volume: 30 Page(s): 1086 - 1093
05/01/2016 Authors: Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH -
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.
J Clin Oncol Volume: 34 Page(s): 1544 - 1557
05/01/2016 Authors: Dimopoulos MA; Sonneveld P; Leung N; Merlini G; Ludwig H; Kastritis E; Goldschmidt H; Joshua D; Orlowski RZ; Powles R -
Novel Combination Treatments in Multiple Myeloma.
Oncology (Williston Park) Volume: 30 Page(s): 451 - 465
05/01/2016 Authors: Nooka AK; Lonial S -
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med Volume: 374 Page(s): 1621 - 1634
04/28/2016 Authors: Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR -
Gene integrated set profile analysis: a context-based approach for inferring biological endpoints.
Nucleic Acids Res Volume: 44 Page(s): e69
04/20/2016 Authors: Kowalski J; Dwivedi B; Newman S; Switchenko JM; Pauly R; Gutman DA; Arora J; Gandhi K; Ainslie K; Doho G -
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lancet Volume: 387 Page(s): 1551 - 1560
04/09/2016 Authors: Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV -
Myeloma Is Not a Single Disease.
J Oncol Pract Volume: 12 Page(s): 287 - 292
04/01/2016 Authors: Lonial S; Nooka AK -
ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE/DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (ELOQUENT-2): A 3-YEAR SAFETY UPDATE.
Volume: 43 Page(s): 64 - 64
03/01/2016 Authors: Doss D; Colson K; Gleason C; Richardson P; Lonial S -
Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.
Leukemia Volume: 30 Page(s): 526 - 535
03/01/2016 Authors: Lonial S; Durie B; Palumbo A; San-Miguel J -
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
Blood Volume: 127 Page(s): 713 - 721
02/11/2016 Authors: Richardson PG; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N -
Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting.
Clin Adv Hematol Oncol Volume: 14 Page(s): 82 - 84
02/01/2016 Authors: Lonial S -
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrm macroglobulinemia.
Oncogene Volume: 35 Page(s): 479 - 490
01/28/2016 Authors: Gaudette BT; Dwivedi B; Chitta KS; Poulain S; Powell D; Vertino P; Leleu X; Lonial S; Chanan-Khan AA; Kowalski J -
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Clin Cancer Res Volume: 22 Page(s): 34 - 43
01/01/2016 Authors: Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z -
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Expert Rev Clin Pharmacol Volume: 9 Page(s): 35 - 48
01/01/2016 Authors: Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF -
Treatment of MM: Upcoming Novel Therapies.
Cancer Treat Res Volume: 169 Page(s): 195 - 205
01/01/2016 Authors: Lonial S -
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Autophagy Volume: 12 Page(s): 1 - 222
01/01/2016 Authors: Klionsky DJ; Abdelmohsen K; Abe A; Abedin MJ; Abeliovich H; Acevedo Arozena A; Adachi H; Adams CM; Adams PD; Adeli K -
Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
Cancer J Volume: 22 Page(s): 3 - 6
01/01/2016 Authors: Lonial S -
Emerging treatments in Castleman disease - a critical appraisal of siltuximab.
Biologics Volume: 10 Page(s): 9 - 15
01/01/2016 Authors: Koff JL; Lonial S -
Erratum.
Autophagy Volume: 12 Page(s): 443
01/01/2016 -
New Targets and New Agents in High-Risk Multiple Myeloma.
Volume: 35 Page(s): e431 - e441
01/01/2016 Authors: Nooka AK; Lonial S -
In-Depth Molecular Profiling of Multiple Myeloma in African Americans
Volume: 126
12/03/2015 Authors: Manojlovic Z; Christofferson A; Legendre C; Spreyer G; Kim S; Liang W; Mulligan G; Kidd PG; Jewell S; Derome M -
Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment
Volume: 126
12/03/2015 Authors: San Miguel JF; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N -
Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States
Volume: 126
12/03/2015 Authors: Radhakrishnan L; Lonial S; Nooka AK -
The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality
Volume: 126
12/03/2015 Authors: Radhakrishnan L; Lonial S; Nooka AK -
Updated Results of a Phase 1/2a, Dose Escalation Study of Pvx-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
Volume: 126
12/03/2015 Authors: Nooka AK; Wang M; Yee AJ; Thomas SK; O'Donnell EK; Shah JJ; Kaufman JL; Lonial S; Richardson PG; Raje NS -
Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective
Volume: 126
12/03/2015 Authors: Xu XS; Yan X; Puchalski T; Lonial S; Lokhorst HM; Voorhees PM; Liu K; Khan I; Jansson R; Ahmadi T -
Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study)
Volume: 126
12/03/2015 Authors: Raje NS; Bensinger W; Cole CE; Lonial S; Jagannath S; Arce-Lara CE; Valent J; Rosko AE; Harb WA; Sandhu I -
Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM)
Volume: 126
12/03/2015 Authors: Quill TA; Kumar SK; Lentzsch S; Lonial S; Roodman GD; Brady ED; Mortimer J; Obholz KL; Anderson KC -
Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Kendi ATK; Li Y; Obidike CO; Gleason C; Boise LH; Lonial S -
Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 126
12/03/2015 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Collins H; Gupta VA; Boise LH; Lonial S -
Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study
Volume: 126
12/03/2015 Authors: van Beers E; van Vliet M; de Best L; Anderson KC; Chari A; Jagganath S; Jakubowiak A; Kumar SK; Lebovic D; Levy J -
A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)
Volume: 126
12/03/2015 Authors: Richardson PC; Hofmeister C; Raje NS; Siegel D; Lonial S; Laubach JP; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J -
Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)
Volume: 126
12/03/2015 Authors: Voorhees PM; Weiss B; Usmani S; Feng H; Uhlar C; Khan I; Ahmadi T; Lonial S -
Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma
Volume: 126
12/03/2015 Authors: Chari A; Lonial S; Suvannasankha A; Fay JW; Arnulf B; Ifthikharuddin JJ; Qin X; Masterson T; Nottage K; Schecter JM -
Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study
Volume: 126
12/03/2015 Authors: Keats JJ; Speyer G; Christophe L; Austin C; Stephenson K; Kurdoglu A; Russell M; Jessica A; Lori C; Adkins J -
Investigation of Mechanisms of Response in Multiple Myeloma Via Bayesian Causal Inference: An Early Analysis of the Commpass Study Data
Volume: 126
12/03/2015 Authors: Gruber F; Hayete B; Keats JJ; McBride K; Karl R; Derome M; Lonial S; Khalil I; Auclair D -
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
Volume: 21 Page(s): 2039 - 2051
12/01/2015 Authors: Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A -
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
Lancet Haematol Volume: 2 Page(s): e516 - e527
12/01/2015 Authors: Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L -
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Nat Cell Biol Volume: 17 Page(s): 1484 - 1496
11/01/2015 Authors: Lin R; Elf S; Shan C; Kang H-B; Ji Q; Zhou L; Hitosugi T; Zhang L; Zhang S; Seo JH -
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
Volume: 171 Page(s): 539 - 546
11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ -
Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Oncology Research and Treatment Volume: 38 Page(s): 165 - 165
10/01/2015 Authors: Raab MS; Richardson PG; Jagannath S; Moreau P; Jakubowiak AJ; Facon T; Vij R; White D; Reece DE; Benboubker L -
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
Transfusion Volume: 55 Page(s): 2351 - 2357
10/01/2015 Authors: Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C -
How I treat high-risk myeloma.
Blood Volume: 126 Page(s): 1536 - 1543
09/24/2015 Authors: Lonial S; Boise LH; Kaufman J -
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
J Clin Oncol Volume: 33 Page(s): 2863 - 2869
09/10/2015 Authors: Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T -
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A -
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med Volume: 373 Page(s): 621 - 631
08/13/2015 Authors: Lonial S; Dimopoulos M; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos M-V; Magen H -
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
Mol Cell Volume: 59 Page(s): 345 - 358
08/06/2015 Authors: Kang H-B; Fan J; Lin R; Elf S; Ji Q; Zhao L; Jin L; Seo JH; Shan C; Arbiser JL -
Multiple myeloma susceptibility loci examined in African and European ancestry populations
Volume: 75
08/01/2015 Authors: Rand KA; Song C; Dean E; Serie D; Curtin K; Hazelett D; Hwang AE; Sheng X; Stram A; Van Den Berg DJ -
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.
Mol Cancer Res Volume: 13 Page(s): 1163 - 1173
08/01/2015 Authors: Shah SP; Lonial S; Boise LH -
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
Mayo Clin Proc Volume: 90 Page(s): 996 - 1000
08/01/2015 Authors: Tefferi A; Kantarjian H; Rajkumar SV; Baker LH; Abkowitz JL; Adamson JW; Advani RH; Allison J; Antman KH; Bast RC -
FUSOKINE GIFT4 TRIGGERS NOVEL B CELL FUNCTION ON HEMATOPOLETIC STEM CELLS
CYTOTHERAPY Volume: 17 Page(s): S13 - S14
06/01/2015 Authors: Deng J; Pennati A; Yuan S; Waller E; Lonial S; Roy K; Galipeau J -
PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY IN PATIENTS WITH >= 3 LINES OF PRIOR THERAPY OR DOUBLE REFRACTORY MULTIPLE MYELOMA: 54767414MMY2002 (SIRIUS)
Volume: 100 Page(s): 153 - 153
06/01/2015 Authors: Lonial S; Weiss B; Usmani S; Singhal S; Chari A; Bahlis N; Belch A; Krishnan A; Vescio R; Mateos MV -
SUBGROUP ANALYSIS BY PRIOR TREATMENT AMONG PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE
Volume: 100 Page(s): 1 - 1
06/01/2015 Authors: Einsele H; Richardson P; Hungria V; Yoon SS; Beksac M; Dimopoulos M; Elghandour A; Jedrzejczak W; Guenther A; Nakorn TN -
ELOQUENT-2: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LENALIDOMIDE/DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Volume: 100 Page(s): 173 - 173
06/01/2015 Authors: Dimopoulos M; Lonial S; Palumbo A; White D; Grosicki S; Spicka I; Walter-Croneck A; Moreau P; Mateos M-V; Magen H -
RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS
Volume: 100 Page(s): 86 - 86
06/01/2015 Authors: Raje N; Bensinger W; Lebovic D; Lonial S; Jagannath S; Acre-Lara C; Rosko A; Harb W; Bahlis N; Supko J -
IMPACT OF CARFILZOMIB ON HEALTH-RELATED QUALITY OF LIFE: RESULTS FROM A PHASE 2 POST-HOC ANALYSIS OF SINGLE-AGENT CARFILZOMIB (PX-171-003-A1) IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Volume: 100 Page(s): 574 - 574
06/01/2015 Authors: Siegel DS; Martin T; Wang M; Vij R; Jakubowiak AJ; Lonial S; Trudel S; Cocks K; Revicki D; Bacci E -
ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE
Volume: 100 Page(s): 80 - 81
06/01/2015 Authors: Moreau P; San-Miguel J; Hungria V; Yoon SS; Beksac M; Dimopoulos M; Elghandour A; Jedrzejczak W; Guenther A; Nakorn TN -
POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
Volume: 100 Page(s): 507 - 508
06/01/2015 Authors: Matous J; Siegel D; Lonial S; Harvey RD; Kasserra C; Li Y; Chen M; Doerr T; Sternas L; Zaki M -
Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study.
Volume: 33
05/20/2015 Authors: Hungria VTM; San Miguel JF; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N -
The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma.
Volume: 33
05/20/2015 Authors: Lonial S; Delforge M; Einsele H; Moreau P; Kaiser M; Dimopoulos MA; Oriol A; Gyger M; Hilder B; Ptaszynski AM -
Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.
Volume: 33
05/20/2015 Authors: San Miguel JF; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N -
Phase II study of daratumumab (DARA) monotherapy in patients with >= 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).
Volume: 33
05/20/2015 Authors: Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan AY; Vescio RA; Mateos M-V -
Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.
Volume: 33
05/20/2015 Authors: Obidike CO; Nooka AK; Kaufman JL; Heffner LT; Langston AA; Lonial S -
Treatment options for relapsed and refractory multiple myeloma.
Blood Volume: 125 Page(s): 3085 - 3099
05/14/2015 Authors: Nooka AK; Kastritis E; Dimopoulos MA; Lonial S -
New cancers after autotransplantations for multiple myeloma.
Biol Blood Marrow Transplant Volume: 21 Page(s): 738 - 745
04/01/2015 Authors: Mahindra A; Raval G; Mehta P; Brazauskas R; Zhang M-J; Zhong X; Bird JM; Freytes CO; Hale GA; Herzig R -
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Blood Volume: 125 Page(s): 2068 - 2074
03/26/2015 Authors: Palumbo A; Bringhen S; Mateos M-V; Larocca A; Facon T; Kumar SK; Offidani M; McCarthy P; Evangelista A; Lonial S -
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.
Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
CANCER Volume: 121 Page(s): 853 - 862
03/15/2015 Authors: Barbee MS; Nooka A; Kaufman JL; Kim S; Chen Z; Heffner LT; Lonial S; Harvey RD -
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
Leuk Lymphoma Volume: 56 Page(s): 383 - 389
02/01/2015 Authors: Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L -
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.
Expert Rev Anticancer Ther Volume: 15 Page(s): 737 - 748
01/01/2015 Authors: Richardson PG; Laubach JP; Lonial S; Moreau P; Yoon S-S; Hungria VTM; Dimopoulos MA; Beksac M; Alsina M; San-Miguel JF -
Novel combination approaches for myeloma.
Hematology Am Soc Hematol Educ Program Volume: 2015 Page(s): 286 - 293
01/01/2015 Authors: Lonial S; Nooka AK -
Genetic Susceptibility Markers of Multiple Myeloma in African-Americans
BLOOD Volume: 124
12/06/2014 Authors: Rand KA; Song C; Hwang AE; Huff CA; Bernal-Mizrachi L; Tomasson MH; Ailawadhi S; Van Den Berg DJ; Sheng X; Graff JJ -
Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib
BLOOD Volume: 124
12/06/2014 Authors: Kelly KR; Chanan-Khan A; Heffner LT; Somlo G; Siegel DS; Zimmerman T; Karnad A; Munshi NC; Jagannath S; Greenberg AL -
Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM)
BLOOD Volume: 124
12/06/2014 Authors: Wang ML; Nooka AK; Yee AJ; Thomas SK; O'Donnell E; Shah J; Weber DM; Kaufman JL; Lonial S; Avigan D -
Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
BLOOD Volume: 124
12/06/2014 Authors: Gleason C; Kaufman JL; Nooka AK; Valla K; Heffner LT; Bisht AS; Manubolu S; Watson M; Boise LH; Lonial S -
Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies
BLOOD Volume: 124
12/06/2014 Authors: Bernal-Mizrachi L; Nooka AK; Pooja C; Chatwal MS; Kim S; Chen Z; Kowalski J; Kaufman JL; Lonial S -
Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
Volume: 124
12/06/2014 Authors: Harvey RD; Cong Z; Werther W; Lethen JL; Lonial S -
Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial
Volume: 124
12/06/2014 Authors: Kaufman JL; Zimmerman T; Rosenbaum CA; Nooka AK; Heffner LT; Harvey RD; Gleason C; Lewis C; Sharp C; Barron KW -
Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant
Volume: 124
12/06/2014 Authors: Pooja C; Nooka AK; Chatwal MS; Kim S; Chen Z; Kowalski J; Kaufman JL; Lonial S; Bernal-Mizrachi L -
Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma
Volume: 124
12/06/2014 Authors: Matulis S; Nooka AK; Von Hollen H; Kaufman JL; Lonial S; Boise LH -
Risk Factors for Development of Myeloma: Role of Smoking and Alcohol
Volume: 124
12/06/2014 Authors: Nooka AK; Lonial S; Boise LH; Lechowicz MJ; Chen E -
Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression
Volume: 124
12/06/2014 Authors: Lonial S; Yellapantula VD; Liang W; Kurdoglu A; Aldrich J; Legendre CM; Stephenson K; Adkins J; McDonald J; Helland A -
Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
Volume: 124
12/06/2014 Authors: Richardson PG; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Thanyaphong NN; Siritanaratkul N -
Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study
Volume: 124
12/06/2014 Authors: San Miguel J; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N -
MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability of Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed or Refractory and Refractory Multiple Myeloma and Renal Impairment
Volume: 124
12/06/2014 Authors: Matous J; Siegel DS; Lonial S; Harvey RD; Kasserra C; Li Y; Chen M; Doerr T; Sternas L; Zaki MH -
Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Volume: 124
12/06/2014 Authors: Richardson PG; Jagannath S; Moreau P; Jakubowiak A; Raab MS; Facon T; Vij R; White D; Reece DE; Benboubker L -
Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells
Volume: 124
12/06/2014 Authors: Gavile CM; Nooka AK; Lonial S; Lee KP; Boise LH -
Detection of NFKB2 3'end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma
Volume: 124
12/06/2014 Authors: Ramachandiran S; Koff JL; Garderet L; Saxe D; Ikhlef S; Kelkar N; Kaplan L; El-Cheikh J; Switchenko JM; Sunay S -
Clinical Impact of an Internet-Based Tool to Provide Expert Guidance for Multiple Myeloma ( MM) from 2012 to 2014
Volume: 124
12/06/2014 Authors: Cameron DR; Lonial S; Mazumder A; Mortimer J; Bowser AD; Obholz KL; Anderson KC -
Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM)
Volume: 124
12/06/2014 Authors: Vogl DT; Raje N; Hari P; Jones SS; Supko JG; Leone G; Wheeler C; Orlowski RZ; Richardson PG; Lonial S -
Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results
Volume: 124
12/06/2014 Authors: Kumar S; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart K; Hari PN; Roy V; Vescio R -
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Lancet Oncol Volume: 15 Page(s): 1503 - 1512
12/01/2014 Authors: Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R -
Older patients with myeloma derive similar benefit from autologous transplantation.
Biol Blood Marrow Transplant Volume: 20 Page(s): 1796 - 1803
11/01/2014 Authors: Sharma M; Zhang M-J; Zhong X; Abidi MH; Akpek G; Bacher U; Callander NS; Dispenzieri A; Freytes CO; Fung HC -
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol Volume: 15 Page(s): e538 - e548
11/01/2014 Authors: Rajkumar SV; Dimopoulos MA; Palumbo A; Blade J; Merlini G; Mateos M-V; Kumar S; Hillengass J; Kastritis E; Richardson P -
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): 356 - 369
10/01/2014 Authors: Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS -
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
Lancet Oncol Volume: 15 Page(s): 1195 - 1206
10/01/2014 Authors: San-Miguel JF; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Gnther A; Nakorn TN; Siritanaratkul N -
Relapsed and refractory multiple myeloma: new therapeutic strategies.
Hematol Oncol Clin North Am Volume: 28 Page(s): 861 - 890
10/01/2014 Authors: Gentili S; Lonial S -
Obesity is associated with clinical characteristics in African American multiple myeloma patients
Volume: 74
10/01/2014 Authors: Hwang AE; Ailwadhi S; Huff CA; Bernal-Mizrachi L; Haiman CA; Peters E; Singhal S; Pawlish K; Bock C; Zimmerman T -
The Tao of myeloma.
Blood Volume: 124 Page(s): 1873 - 1879
09/18/2014 Authors: Boise LH; Kaufman JL; Bahlis NJ; Lonial S; Lee KP -
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Clin Lymphoma Myeloma Leuk Volume: 14 Suppl Page(s): S71 - S77
09/01/2014 Authors: Usmani SZ; Lonial S -
Transcriptional and Post-translational Regulation of the BcI-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 14 Page(s): S148 - S148
09/01/2014 Authors: Gupta VA; Matulis SM; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth.
Mol Cell Volume: 55 Page(s): 552 - 565
08/21/2014 Authors: Shan C; Elf S; Ji Q; Kang H-B; Zhou L; Hitosugi T; Jin L; Lin R; Zhang L; Seo JH -
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
Volume: 124 Page(s): 1038 - 1046
08/14/2014 Authors: Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J -
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (PANORAMA 1)
Volume: 99 Page(s): 219 - 220
06/01/2014 Authors: San-Miguel J; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N -
RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA
Volume: 99 Page(s): 107 - 108
06/01/2014 Authors: Raje N; Vogl D; Bensinger W; Voorhees P; Hari P; Berdeja J; Jagannath S; Jones S; Wheeler C; Supko J -
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant Volume: 20 Page(s): 852 - 857
06/01/2014 Authors: Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S -
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Blood Volume: 123 Page(s): 3269 - 3276
05/22/2014 Authors: Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun S-Y; Boise LH; Lonial S -
Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Volume: 32
05/20/2014 Authors: Richardson PG; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N -
ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCITrial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models.
Volume: 32
05/20/2014 Authors: Weiss M; Jacobus SJ; Gertz MA; Munshi NC; Lonial S; Kumar S; Fonseca R; Dispenzieri A; Lacy M; Stewart AK -
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
Volume: 32
05/20/2014 Authors: Richardson PG; Hofmeister C; Raje NS; Siegel DSD; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J -
Causes of mortality in patients with plasma cell disorders.
Volume: 32
05/20/2014 Authors: Nooks AK; Kaufman JL; Langston AA; Lonial S -
Access to Children's Oncology Group phase I clinical trials: Racial/ethnic dissimilarities in participation.
Volume: 32
05/20/2014 Authors: Nooks AK; Behera M; Lonial S; Dixon M; Georglevska B; Ramallngam SS; Pentz RD -
Survival trends of myeloma patients in the new millennium.
Volume: 32
05/20/2014 Authors: Gleason C; Nooka AK; Langston AA; Shah NN; Kaufman JL; Lonial S -
Down to the bitter end.
Blood Volume: 123 Page(s): 3061 - 3062
05/15/2014 Authors: Lonial S; Gleason C -
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e59 - e63
04/01/2014 Authors: Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL -
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Blood Volume: 123 Page(s): 1826 - 1832
03/20/2014 Authors: Richardson PG; Siegel DS; Vij R; Hofmeister CC; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N -
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Blood Volume: 123 Page(s): 1461 - 1469
03/06/2014 Authors: Richardson PG; Xie W; Jagannath S; Jakubowiak A; Lonial S; Raje NS; Alsina M; Ghobrial IM; Schlossman RL; Munshi NC -
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.
Bone Marrow Transplant Volume: 49 Page(s): 416 - 421
03/01/2014 Authors: Freytes CO; Vesole DH; LeRademacher J; Zhong X; Gale RP; Kyle RA; Reece DE; Gibson J; Schouten HC; McCarthy PL -
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
Leukemia Volume: 28 Page(s): 690 - 693
03/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S -
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).
Leukemia Volume: 28 Page(s): 525 - 542
03/01/2014 Authors: Ocio EM; Richardson PG; Rajkumar SV; Palumbo A; Mateos MV; Orlowski R; Kumar S; Usmani S; Roodman D; Niesvizky R -
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
Lancet Oncol Volume: 15 Page(s): 333 - 342
03/01/2014 Authors: Palumbo A; Bringhen S; Kumar SK; Lupparelli G; Usmani S; Waage A; Larocca A; van der Holt B; Musto P; Offidani M -
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
Biol Blood Marrow Transplant Volume: 20 Page(s): 402 - 408.e1
03/01/2014 Authors: Saad A; Mahindra A; Zhang M-J; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ -
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex.
Mol Cell Volume: 53 Page(s): 534 - 548
02/20/2014 Authors: Fan J; Shan C; Kang H-B; Elf S; Xie J; Tucker M; Gu T-L; Aguiar M; Lonning S; Chen H -
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
J Clin Oncol Volume: 32 Page(s): 587 - 600
02/20/2014 Authors: Palumbo A; Rajkumar SV; San Miguel JF; Larocca A; Niesvizky R; Morgan G; Landgren O; Hajek R; Einsele H; Anderson KC -
High-risk myeloma: when to transplant-or not.
Semin Oncol Volume: 41 Page(s): e1 - e9
02/01/2014 Authors: Eicher DM; Lonial S; Cavallo F; Palumbo A; Nair B; Waheed S; Hofmeister C; Rogers HJ -
Current strategies for treatment of relapsed/refractory multiple myeloma.
Expert Rev Hematol Volume: 7 Page(s): 97 - 111
02/01/2014 Authors: Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG -
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
Bone Marrow Transplant Volume: 49 Page(s): 185 - 189
02/01/2014 Authors: Langston AA; Prichard JM; Muppidi S; Nooka A; Lechowicz MJ; Lonial S; Sinha R; Graiser M; Kaufman JL; Khoury HJ -
Simplified Technique for Administration of High Dose Melphalan
Volume: 20 Page(s): S291 - S292
02/01/2014 Authors: Hutcherson D; Valla K; Shah KS; Surati M; French K; Nooka A; Kaufman J; Lonial S; Cohen JB; Langston A -
Association of response endpoints with survival outcomes in multiple myeloma.
Leukemia Volume: 28 Page(s): 258 - 268
02/01/2014 Authors: Lonial S; Anderson KC -
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Volume: 123 Page(s): 632 - 639
01/30/2014 Authors: Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio W; Li B; Neuwirth R -
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Cancer Cell Volume: 25 Page(s): 91 - 101
01/13/2014 Authors: Lohr JG; Stojanov P; Carter SL; Cruz-Gordillo P; Lawrence MS; Auclair D; Sougnez C; Knoechel B; Gould J; Saksena G -
Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma.
Cancer Inform Volume: 13 Page(s): 49 - 53
01/01/2014 Authors: Yang R; Chen L; Newman S; Gandhi K; Doho G; Moreno CS; Vertino PM; Bernal-Mizarchi L; Lonial S; Boise LH -
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
Cancer Volume: 119 Page(s): 4119 - 4128
12/01/2013 Authors: Nooka AK; Kaufman JL; Behera M; Langston A; Waller EK; Flowers CR; Gleason C; Boise LH; Lonial S -
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT -
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
Leukemia Volume: 27 Page(s): 2351 - 2356
12/01/2013 Authors: Jakubowiak AJ; Siegel DS; Martin T; Wang M; Vij R; Lonial S; Trudel S; Kukreti V; Bahlis N; Alsina M -
Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.
Expert Opin Biol Ther Volume: 13 Page(s): 1731 - 1740
12/01/2013 Authors: Lonial S; Kaufman J; Laubach J; Richardson P -
The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma
Volume: 122
11/15/2013 Authors: Harrison B; Anderson KC; Raje N; Richardson P; Warren D; Chari A; Jagannath S; La L; Berdeja J; Zimlich M -
Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC)
BLOOD Volume: 122
11/15/2013 Authors: Nooks AK; Kaufman JL; Shah NN; Hassan B; Boise LH; Williams I; Lonial S -
Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans
Volume: 122
11/15/2013 Authors: Hwang AE; Ailawadhi S; Bernal-Mizrachi L; Zimmerman TM; Haiman C; Van den Berg DJ; Pawlish K; Mohrbacher AM; Terebelo H; Birmann BM -
Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Rossi MR; Newman S; Nooka AK; Kaufman JL; Bahlis NJ; Neri P; Matulis SM; Bernal-Mizrachi L; Gupta VA; Varma A -
Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT)
Volume: 122
11/15/2013 Authors: Gowda S; Langston A; Kaufman JL; Shah NN; Lechowicz MJ; Boise LH; Lonial S; Nooka AK -
MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)
Volume: 122
11/15/2013 Authors: Richardson PG; Hofmeister CC; Siegel D; Lonial S; Laubach JP; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Raje N -
Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Harvey D; Kaufman JL; Langston A; Nickleach D; Gleason C; Heffner LT; Boise LH; Lonial S -
Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample
Volume: 122
11/15/2013 Authors: Nooka AK; Kaufman JL; Shah NN; Langston A; Collins H; Boise LH; Lonial S -
Access To Therapeutic Surgical Procedures For Pathologic Fractures In Multiple Myeloma Patients: Analysis of Nationwide Inpatient Sample (NIS)
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Lonial S -
Prolonged Survival and Improved Response Rates With ARRY-520 In Relapsed/Refractory Multiple Myeloma (RRMM) Patients With Low alpha-1 Acid Glycoprotein (AAG) Levels: Results From a Phase 2 Study
Volume: 122
11/15/2013 Authors: Lonial S; Shah JJ; Zonder J; Bensinger WI; Cohen AD; Kaufman JL; Nooka AK; Weber DM; Hilder B; Rush SA -
P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Shah SP; Gupta VA; Matulis SM; Nooka AK; Lonial S; Boise LH -
Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma
Volume: 122
11/15/2013 Authors: Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH -
Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients
Volume: 122
11/15/2013 Authors: Shah NN; Nooka AK; Kaufman JL; Casbourne D; Hutcherson D; Maynard R; Waller EK; Lonial S; Langston A -
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Haematologica Volume: 98 Page(s): 1753 - 1761
11/01/2013 Authors: Siegel D; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K -
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
Biol Blood Marrow Transplant Volume: 19 Page(s): 1615 - 1624
11/01/2013 Authors: Costa LJ; Zhang M-J; Zhong X; Dispenzieri A; Lonial S; Krishnan A; Freytes C; Vesole D; Gale RP; Anderson K -
"A fortuitous combination of circumstances".
Blood Volume: 122 Page(s): 2768 - 2769
10/17/2013 Authors: Lonial S -
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.
Blood Volume: 122 Page(s): 2331 - 2337
10/03/2013 Authors: Richardson PG; Schlossman RL; Alsina M; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan M; Paley CS -
The future of drug development and therapy in myeloma.
Semin Oncol Volume: 40 Page(s): 652 - 658
10/01/2013 Authors: Lonial S; Boise LH -
A phase ll study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma
ONKOLOGIE Volume: 36 Page(s): 38 - 39
10/01/2013 Authors: Siegel D; Martin T; Wang M; Vij R; Jakubowiak A; Lonial S; Trudel S; Kukreti V; Bahlis N; Alsina M -
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
Lancet Oncol Volume: 14 Page(s): 1129 - 1140
10/01/2013 Authors: Dimopoulos M; Siegel DS; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C; Blacklock H; Goldschmidt H -
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.
Ann Pharmacother Volume: 47 Page(s): 1136 - 1142
09/01/2013 Authors: Barbee MS; Harvey RD; Lonial S; Kaufman JL; Wilson NM; McKibbin T; Hutcherson DA; Surati M; Valla K; Shah KS -
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
Biol Blood Marrow Transplant Volume: 19 Page(s): 1393 - 1395
09/01/2013 Authors: Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S -
Non-secretory myeloma: a clinician's guide.
Oncology (Williston Park) Volume: 27 Page(s): 924 - 930
09/01/2013 Authors: Lonial S; Kaufman JL -
Rare myelomas: sometimes when you hear hooves, it's a zebra..
Oncology (Williston Park) Volume: 27 Page(s): 808 - 812
08/01/2013 Authors: Gentili S; Lonial S -
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 370 - 376
08/01/2013 Authors: Kaufman JL; Fabre C; Lonial S; Richardson PG -
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Clin Cancer Res Volume: 19 Page(s): 3659 - 3670
07/01/2013 Authors: Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani SZ -
ELIMINATING THE NEED FOR 24-HOUR URINE STUDIES IN PHASE I MYELOMA PATIENTS
Volume: 98 Page(s): 598 - 598
06/12/2013 Authors: Shah N; Kaufman J; Langston A; Waller E; Boise L; Harvey R; Lonial S; Nooka A -
MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Volume: 98 Page(s): 97 - 98
06/12/2013 Authors: Richardson P; Hofmeister C; Siegel D; Lonial S; Laubach J; Efebera Y; Vesole D; Nooka A; Rosenblatt J; Raje N -
WEEKLY ORAL INVESTIGATIONAL PROTEASOME INHIBITOR MLN9708 PLUS LENALIDOMIDE-DEXAMETHASONE IN ELDERLY PATIENTS (PTS) WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM): SUBSET ANALYSIS OF A PHASE 1/2 STUDY
Volume: 98 Page(s): 102 - 102
06/12/2013 Authors: Richardson P; Berdeja J; Niesvizky R; Lonial S; Hamadani M; Stewart A; Hari P; Vescio R; Roy V; Berg D -
THE EFFICACY AND SAFETY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IS NOT IMPACTED BY AGE IN PATIENTS WITH ADVANCED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: MM-002 SUBGROUP ANALYSIS
Volume: 98 Page(s): 325 - 326
06/12/2013 Authors: Jagannath S; Hofmeister C; Baz R; Siegel DS; Vij R; Chen C; Lonial S; Anderson K; Chen M; Zaki M -
SECOND PRIMARY MALIGNANCIES (SPM) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ACCORDING TO LENALIDOMIDE EXPOSURE: A META-ANALYSIS OF 6383 INDIVIDUAL PATIENT DATA
Volume: 98 Page(s): 476 - 477
06/12/2013 Authors: Bringhen S; Rajkumar V; Lupparelli G; Usmani S; Waage A; Larocca A; Van der Holt B; Musto P; Evangelista A; Zweegman S -
CLINICAL RESPONSE BY BASELINE CHARACTERISTICS IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA TREATED WITH PANOBINOSTAT, BORTEZOMIB, AND DEXAMETHASONE (PANORAMA 2)
Volume: 98 Page(s): 324 - 324
06/12/2013 Authors: Richardson P; Schlossman R; Alsina M; Coutre S; Gasparetto C; Mukhopadhyay S; Ondovik M; Khan M; Paley C; Lonial S -
ALPHA 1-ACID GLYCOPROTEIN (AAG) IS A POTENTIAL PATIENT SELECTION BIOMARKER FOR IMPROVED CLINICAL ACTIVITY OF ARRY-520 IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM)
Volume: 98 Page(s): 328 - 329
06/12/2013 Authors: Tunquist B; Brown K; Hingorani G; Aitchison R; Regensburger J; Lonial S; Kaufman J; Zonder J; Cohen A; Bensinger W -
PHASE (PH) I/II STUDY OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE (LEN/DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM): UPDATED PH II RESULTS AND PH I/II LONG TERM SAFETY
Volume: 98 Page(s): 319 - 319
06/12/2013 Authors: Facon T; Richardson P; Jagannath S; Moreau P; Jakubowiak A; Raab M; Vij R; White D; Reece D; Benboubker L -
SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL
Volume: 98 Page(s): 321 - 321
06/12/2013 Authors: Richardson P; Siegel D; Vij R; Hofmeister C; Baz R; Jagannath S; Chen C; Lonial S; Jakubowiak A; Bahlis N -
Cardiac and pulmonary safety profile of patients with relapsed and/or refractory multiple myeloma from four phase 2 studies of single-agent carfilzomib
LEUKEMIA & LYMPHOMA Volume: 54 Page(s): 19 - 19
06/01/2013 Authors: Lonial S; Niesvizky R; McCulloch L; Rajangam K; Vij R -
MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM)
Volume: 31
05/20/2013 Authors: Richardson PGG; Hofmeister CC; Siegel DSD; Lonial S; Laubach J; Efebera YA; Vesole DH; Nooka AK; Rosenblatt J; Raje NS -
Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
Volume: 31
05/20/2013 Authors: Nooka AK; Langston AA; Waller EK; Heffner LT; Gleason C; Muppidi S; Watson M; Casbourne D; Boise L; Kaufman JL -
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
Volume: 31
05/20/2013 Authors: Jagannath S; Hofmeister CC; Baz RC; Siegel DSD; Vij R; Chen C; Lonial S; Anderson KC; Chen M; Zaki MH -
Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis
Volume: 31
05/20/2013 Authors: Ravipati HP; Kaufman JL; Langston AA; Boise L; Flowers C; Lonial S; Nooka AK -
Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.
Volume: 31
05/20/2013 Authors: Duc QT; Langston AA; Waller EK; Simon M; Gleason C; Casbourne D; Fisher M; Kaufman JL; Flowers C; Lonial S -
Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2)
Volume: 31
05/20/2013 Authors: Alsina M; Richardson PGG; Schlossman RL; Weber DM; Coutre SE; Gasparetto C; Mukhopadhyay S; Ondovik MS; Khan MH; Paley CS -
Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD)
Volume: 31
05/20/2013 Authors: Palumbo A; Bringhen S; Rajkumar V; Lupparelli G; Usmani SZ; Waage A; Larocca A; van der Holt B; Musto P; Evangelista A -
Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial
Volume: 31
05/20/2013 Authors: Siegel DSD; Richardson PGG; Vij R; Hofmeister CC; Baz RC; Jagannath S; Chen C; Lonial S; Jakubowiak AJ; Bahlis NJ -
Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety
Volume: 31
05/20/2013 Authors: Lonial S; Jagannath S; Moreau P; Jakubowiak AJ; Raab MS; Facon T; Vij R; Bleickardt E; Reece DE; Benboubker L -
Salvage second hematopoietic cell transplantation in myeloma.
Biol Blood Marrow Transplant Volume: 19 Page(s): 760 - 766
05/01/2013 Authors: Michaelis LC; Saad A; Zhong X; Le-Rademacher J; Freytes CO; Marks DI; Lazarus HM; Bird JM; Holmberg L; Kamble RT -
Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma.
Leuk Suppl Volume: 2 Page(s): S28 - S29
05/01/2013 Authors: Lonial S -
Advances in current treatment for patients with newly diagnosed multiple myeloma.
Leuk Suppl Volume: 2 Page(s): S1 - S2
05/01/2013 Authors: Lonial S -
Single centre pharmacoeconomic analysis of palifermin in autologous stem cell transplantation
Volume: 48 Page(s): S453 - S453
04/01/2013 Authors: Johnson HR; Nooka A; Kaufman J; Flowers C; Langston A; Graiser M; Plummer T; Lonial S; Waller E -
A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM)
BRITISH JOURNAL OF HAEMATOLOGY Volume: 161 Page(s): 7 - 7
04/01/2013 Authors: Siegel DS; Martin T; Wang M; Vij R; Jakubowiak AJ; Lonial S; Trudel S; Kukreti V; Bahlis N; Alsina M -
Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
BRITISH JOURNAL OF HAEMATOLOGY Volume: 161 Page(s): 20 - 20
04/01/2013 Authors: Siegel DS; Martin T; Nooka A; Harvey RD; Vij R; Niesvizky R; Badros AZ; Jagannath S; McCulloch L; Rajangam K -
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
Biol Blood Marrow Transplant Volume: 19 Page(s): 460 - 467
03/01/2013 Authors: Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK -
Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
Volume: 19 Page(s): S191 - S191
02/01/2013 Authors: Waller EK; Johnson HR; Jagirdar N; Gaylor C; Lipscomb C; Flowers C; Kaufman J; Khoury HJ; Langston A; Lechowicz M -
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
Nat Commun Volume: 4 Page(s): 1790
01/01/2013 Authors: Hitosugi T; Zhou L; Fan J; Elf S; Zhang L; Xie J; Wang Y; Gu T-L; Alekovi M; LeRoy G -
Induction therapy for newly diagnosed multiple myeloma.
J Natl Compr Canc Netw Volume: 11 Page(s): 19 - 28
01/01/2013 Authors: Lonial S; Miguel JFS -
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
Biologics Volume: 7 Page(s): 13 - 32
01/01/2013 Authors: Nooka A; Gleason C; Casbourne D; Lonial S -
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
Transfusion Volume: 53 Page(s): 76 - 84
01/01/2013 Authors: Kaufman JL; Flowers CR; Rados KD; Calandra GB; Vose JM; Hewes LB; Lonial S; Langston AA; Khoury HJ; Lechowicz MJ -
Sequence analysis of -subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Blood Volume: 120 Page(s): 4513 - 4516
11/29/2012 Authors: Lichter DI; Danaee H; Pickard MD; Tayber O; Sintchak M; Shi H; Richardson PG; Cavenagh J; Blad J; Faon T -
Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study
Volume: 120
11/16/2012 Authors: Lonial S; Baz R; Bahlis NJ; Chen CI; Anderson KC; Chen M; Zaki M; Richardson PG -
Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status
Volume: 120
11/16/2012 Authors: Yim DB; Nooka AK; Martin JM; Lonial S -
Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma
Volume: 120
11/16/2012 Authors: Lonial S; Niesvizky R; McCulloch L; Rajangam K; Vij R -
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK -
Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
Volume: 120
11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK -
Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets.
Volume: 120
11/16/2012 Authors: Shah SP; Lonial S; Boise LH -
The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study
Volume: 120
11/16/2012 Authors: Shah JJ; Zonder JA; Cohen A; Bensinger W; Kaufman JL; Orlowski RZ; Harvey RD; Abidi MH; Thomas SK; Walker D -
TGR-1202: A Novel, Targeted PI3K delta Inhibitor in Multiple Myeloma
Volume: 120
11/16/2012 Authors: Vakkalanka S; Viswanadha S; Boise LH; Sportelli P; Miskin H; Lonial S -
Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study
Volume: 120
11/16/2012 Authors: Raje N; Hari PN; Vogl DT; Jagannath S; Orlowski RZ; Supko JG; Stephenson P; Jones SS; Wheeler C; Lonial S -
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH -
Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins
Volume: 120
11/16/2012 Authors: Matulis SM; Liu J; Gupta VA; Conage-Pough JE; Nooka AK; Waller EK; Kaufman JL; Lonial S; Boise LH -
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
Cancer Cell Volume: 22 Page(s): 585 - 600
11/13/2012 Authors: Hitosugi T; Zhou L; Elf S; Fan J; Kang H-B; Seo JH; Shan C; Dai Q; Zhang L; Xie J -
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
Cancer Volume: 118 Page(s): 5278 - 5282
11/01/2012 Authors: Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ -
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Blood Volume: 120 Page(s): 2817 - 2825
10/04/2012 Authors: Siegel DS; Martin T; Wang M; Vij R; Jakubowiak AJ; Lonial S; Trudel S; Kukreti V; Bahlis N; Alsina M -
Sequential or combination therapy for multiple myeloma.
Expert Rev Hematol Volume: 5 Page(s): 533 - 545
10/01/2012 Authors: Nooka A; Lonial S -
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Clin Lymphoma Myeloma Leuk Volume: 12 Page(s): 310 - 318
10/01/2012 Authors: Jagannath S; Vij R; Stewart AK; Trudel S; Jakubowiak AJ; Reiman T; Somlo G; Bahlis N; Lonial S; Kunkel LA -
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Leuk Lymphoma Volume: 53 Page(s): 1820 - 1823
09/01/2012 Authors: Wolf JL; Siegel D; Goldschmidt H; Hazell K; Bourquelot PM; Bengoudifa BR; Matous J; Vij R; de Magalhaes-Silverman M; Abonour R -
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
Br J Haematol Volume: 158 Page(s): 608 - 614
09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L -
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients 65 years old with relapsed or refractory multiple myeloma.
Int J Hematol Volume: 96 Page(s): 254 - 262
08/01/2012 Authors: Chanan-Khan AA; Lonial S; Weber D; Borrello I; Fo R; Hellmann A; Dimopoulos M; Swern AS; Knight R -
CARFILZOMIB DOSE AND SCHEDULE NEED NOT BE ADJUSTED FOR BASELINE RENAL DYSFUNCTION, INCLUDING PATIENTS ON HEMODIALYSIS
Volume: 97 Page(s): 346 - 346
07/16/2012 Authors: Harvey D; Lonial S; Patel P; McCulloch L; Niesvizky R; Kaufman J -
MLN9708, AN INVESTIGATIONAL PROTEASOME INHIBITOR, COMBINED WITH LENALIDOMIDE AND DEXAMETHASONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA PATIENTS: EVALUATION OF WEEKLY AND TWICE-WEEKLY DOSING REGIMENS
Volume: 97 Page(s): 473 - 474
07/16/2012 Authors: Richardson P; Berdeja J; Niesvizky R; Lonial S; Vesole D; Hamadani M; Chari A; Hari P; Htut M; Roy V -
EFFICACY AND SAFETY OF LENALIDOMIDE 25 MG IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND NORMAL RENAL FUNCTION
Volume: 97 Page(s): 350 - 350
07/16/2012 Authors: Chanan-Khan A; Lonial S; Foa R; Swern A; Li JS; Lewis P; Dimopoulos M -
PLASMA CELL LEUKEMIA: SUSTAINED RESPONSES ARE POSSIBLE WITH INNOVATIVE TREATMENT STRATEGIES
Volume: 97 Page(s): 601 - 601
07/16/2012 Authors: Nooka A; Kaufman J; Muppidi S; Harvey R; Gleason C; Heffner L; Langston A; Casbourne D; Boise L; Lonial S -
A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Volume: 97 Page(s): 474 - 474
07/16/2012 Authors: Moreau P; Richardson P; Jakubowiak A; Jagannath S; Raab M; Facon T; Vij R; Reece D; White D; Benboubker L -
RESPONSE RATES TO SINGLE-AGENT CARFILZOMIB IN PATIENTS DOUBLE REFRACTORY OR INTOLERANT TO BORTEZOMIB AND IMMUNOMODULATORS IN TRIAL PX-171-003-A1
Volume: 97 Page(s): 342 - 343
07/16/2012 Authors: Siegel D; Martin T; Wang M; Vij R; Jakubowiak A; Jagannath S; Lonial S; Kukreti V; Bahlis N; Alsina M -
PANORAMA 1: A PHASE III STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
Volume: 97 Page(s): 117 - 118
07/16/2012 Authors: Richardson P; Hungria V; Moreau P; Lee J; Yoon S; Dimopoulos M; Beksac M; Elghandour A; Jedrzejczak W; Guenther A -
PANORAMA 2: A PHASE II STUDY OF PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED AND BORTEZOMIB-REFRACTORY MULTIPLE MYELOMA
Volume: 97 Page(s): 338 - 338
07/16/2012 Authors: Richardson P; Alsina M; Weber D; Coutre S; Lonial S; Gasparetto C; Warsi G; Ondovik M; Mukhopadhyay S; Paley C -
MLN4924, AN INVESTIGATIONAL NEDD8-ACTIVATING ENZYME (NAE) INHIBITOR, IN PATIENTS WITH RELAPSED AND/OR REFRACTORY LYMPHOMA OR MULTIPLE MYELOMA (MM): PHASE 1 DOSE-ESCALATION STUDY OF TWICE-WEEKLY DOSING
Volume: 97 Page(s): 432 - 433
07/16/2012 Authors: Harvey R; Lebovic D; Lonial S; Jakubowiak A; Pickard M; McDonald A; Mulligan G; Blakemore S; Kuan S; Dezube B -
ELOTUZUMAB-ASSOCIATED INFUSION REACTIONS: INCIDENCE AND MANAGEMENT
Volume: 97 Page(s): 605 - 605
07/16/2012 Authors: Jagannath S; Lonial S; Parli T; Brotherton R; Kroog G; Racenberg J; Wang MH; Singhal A; Richardson P -
VANTAGE 088: FINAL RESULTS FROM THE GLOBAL PHASE 3 TRIAL OF THE MULTI-HISTONE DEACETYLASE INHIBITOR VORINOSTAT IN COMBINATION WITH BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
Volume: 97 Page(s): 113 - 114
07/16/2012 Authors: Dimopoulos M; Jagannath S; Yoon S; Siegel D; Lonial S; Qi J; Hajek R; Facon T; Rosinol L; Williams C -
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Cancer Volume: 118 Page(s): 3538 - 3548
07/15/2012 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT -
The era of combination therapy in myeloma.
J Clin Oncol Volume: 30 Page(s): 2434 - 2436
07/10/2012 Authors: Lonial S; Kaufman JL -
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood Volume: 119 Page(s): 5661 - 5670
06/14/2012 Authors: Vij R; Wang M; Kaufman JL; Lonial S; Jakubowiak AJ; Stewart AK; Kukreti V; Jagannath S; McDonagh KT; Alsina M -
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
J Clin Oncol Volume: 30 Page(s): 1953 - 1959
06/01/2012 Authors: Lonial S; Vij R; Harousseau J-L; Facon T; Moreau P; Mazumder A; Kaufman JL; Leleu X; Tsao LC; Westland C -
Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma.
Bone Marrow Transplant Volume: 47 Page(s): 831 - 837
06/01/2012 Authors: Ringdn O; Shrestha S; da Silva GT; Zhang M-J; Dispenzieri A; Remberger M; Kamble R; Freytes CO; Gale RP; Gibson J -
A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Volume: 30
05/20/2012 Authors: Moreau P; Richardson PGG; Jakubowiak AJ; Jagannath S; Raab M; Facon T; Vij R; Reece DE; White D; Benboubker L -
Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
Volume: 30
05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L -
Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
Volume: 30
05/20/2012 Authors: Nooka AK; Badros AZ; Patel P; McCulloch L; Lonial S; Kaufman JL -
Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
Volume: 30
05/20/2012 Authors: Nooka AK; Badros AZ; Patel P; McCulloch L; Lonial S; Kaufman JL -
PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
Volume: 30
05/20/2012 Authors: Alsina M; Schlossman RL; Weber DM; Coutre SE; Lonial S; Gasparetto C; Warsi G; Ondovik MS; Mukhopadhyay S; Paley CS -
ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).
Volume: 30
05/20/2012 Authors: Dimopoulos MA; Facon T; Richardson PGG; Orlowski RZ; San-Miguel JF; Lonial S; Anderson KC; Moreau P; Reece DE; Singhal A -
A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
Volume: 30
05/20/2012 Authors: Owonikoko TK; Harvey RD; Kauh JS; Lewis CM; Hossain MS; Akintayo AO; Merriewether AR; Chen Z; Hawk NN; Saba NF -
Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study.
Volume: 30
05/20/2012 Authors: Richardson PGG; Berdeja JG; Niesvizky R; Lonial S; Roy V; Hari P; Berg D; Liu G; Gupta N; Di Bacco A -
An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Barbee MS; Wilson NM; Harvey RD; McKibbin T; Lonial S; Kaufman JL; Shah KS -
ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).
Volume: 30
05/20/2012 Authors: Lonial S; Richardson PGG; Moreau P; Orlowski RZ; San-Miguel JF; Dimopoulos MA; Palumbo AP; Facon T; Vij R; White D -
Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
Volume: 30
05/20/2012 Authors: Harvey RD; Lonial S; Patel P; McCulloch L; Niesvizky R; Kaufman JL -
Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM).
Volume: 30
05/20/2012 Authors: Kaufman JL; Nooka AK; Muppidi S; Heffner LT; Gleason C; Boise L; Lonial S -
Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.
Volume: 30
05/20/2012 Authors: Siegel DSD; Martin T; Singhal S; Wang M; Vij R; Jakubowiak AJ; Jagannath S; Lonial S; Kukreti V; Bahlis NJ -
Panobinostat for the treatment of multiple myeloma.
Expert Opin Investig Drugs Volume: 21 Page(s): 733 - 747
05/01/2012 Authors: Neri P; Bahlis NJ; Lonial S -
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.
Leukemia Volume: 26 Page(s): 1091 - 1097
05/01/2012 Authors: Mahindra A; Kalaycio ME; Vela-Ojeda J; Vesole DH; Zhang M-J; Li P; Berenson JR; Bird JM; Dispenzieri A; Gajewski JL -
The MMRF CoMMpassSM Study: A prospective, longitudinal, multicenter observational study in newly diagnosed multiple myeloma patients to assess the relationship between patient outcomes, treatment regimens and molecular profiles
CANCER RESEARCH Volume: 72
04/15/2012 Authors: Hoban CJ; Kidd P; Jewell S; Monroe T; Khoo S; Rohrer D; Levy J; Harrison B; Lonial S; Keats J -
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Leukemia Volume: 26 Page(s): 595 - 608
04/01/2012 Authors: Richardson PG; Delforge M; Beksac M; Wen P; Jongen JL; Sezer O; Terpos E; Munshi N; Palumbo A; Rajkumar SV -
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
Leuk Lymphoma Volume: 53 Page(s): 725 - 727
04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M -
Guidelines for the use and interpretation of assays for monitoring autophagy.
Autophagy Volume: 8 Page(s): 445 - 544
04/01/2012 Authors: Klionsky DJ; Abdalla FC; Abeliovich H; Abraham RT; Acevedo-Arozena A; Adeli K; Agholme L; Agnello M; Agostinis P; Aguirre-Ghiso JA -
Plasma Cell Myeloma Evaluation by Flow Cytometric lmmunophenotyping: Aberrant Antigen Expression and Correlation with Cytogenetic/FISH Abnormalities
Volume: 92 Page(s): 342A - 342A
02/01/2012 Authors: Husman AL; Toscano M; Chandler KL; Lonial S; Kaufman JL; Mann KP -
Plasma Cell Myeloma Evaluation by Flow Cytometric Immunophenotyping: Aberrant Antigen Expression and Correlation with Cytogenetic/FISH Abnormalities
Volume: 25 Page(s): 342A - 342A
02/01/2012 Authors: Husman AL; Toscano M; Chandler KL; Lonial S; Kaufman JL; Mann KP -
Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin.
Exp Hematol Volume: 40 Page(s): 95 - 96
02/01/2012 Authors: Giver CR; Jaye DL; Waller EK; Lonial S -
BI-MODAL AGE DISTRIBUTION OF PATIENTS WITH RELAPSED HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION CORRELATES WITH MARKEDLY INFERIOR SURVIVAL AMONG PATIENTS AGE 35 YEARS AND OLDER
Volume: 18 Page(s): S296 - S296
02/01/2012 Authors: Sharma A; Duan M; Chowdhury R; Graiser M; Zhang H; Langston A; Lonial S; Flowers CR; Haight A; Waller EK -
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.
Mol Cell Volume: 44 Page(s): 864 - 877
12/23/2011 Authors: Hitosugi T; Fan J; Chung T-W; Lythgoe K; Wang X; Xie J; Ge Q; Gu T-L; Polakiewicz RD; Roesel JL -
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Blood Volume: 118 Page(s): 6368 - 6379
12/08/2011 Authors: Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA -
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells.
Mol Cell Biol Volume: 31 Page(s): 4938 - 4950
12/01/2011 Authors: Fan J; Hitosugi T; Chung T-W; Xie J; Ge Q; Gu T-L; Polakiewicz RD; Chen GZ; Boggon TJ; Lonial S -
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells.
Mol Cancer Ther Volume: 10 Page(s): 2415 - 2425
12/01/2011 Authors: Zhao L; Yue P; Lonial S; Khuri FR; Sun S-Y -
Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study
Volume: 118 Page(s): 818 - 819
11/18/2011 Authors: Jakubowiak AJ; Siegel DS; Singhal S; Martin T; Lonial S; Kukreti V; Bahlis N; Chanan-Khan AA; Alsina M; Somlo G -
Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis
Volume: 118 Page(s): 819 - 819
11/18/2011 Authors: Singhal S; Siegel DS; Martin T; Vij R; Wang L; Jakubowiak AJ; Lonial S; Kukreti V; Zonder JA; Wong AF -
Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma
Volume: 118 Page(s): 1248 - 1248
11/18/2011 Authors: Ramachandiran S; Guo X; Garderet L; Ikhlef S; El-cheikh J; Weil MR; Young AN; Bagirov M; Lonial S; Chen Z -
Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
Volume: 118 Page(s): 223 - 223
11/18/2011 Authors: Berdeja JG; Richardson PG; Lonial S; Niesvizky R; Hui A-M; Berg D; Gupta N; Liu G; Di Bacco A; Kumar S -
The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development
Volume: 118 Page(s): 470 - 471
11/18/2011 Authors: Wear SM; Richardson PG; Revta C; Vij R; Fiala M; Lonial S; Mitchell AR; Siegel DS; Aleman A; Jakubowiak AJ -
ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study
Volume: 118 Page(s): 809 - 810
11/18/2011 Authors: Shah JJ; Zonder J; Cohen A; Orlowski RZ; Alexanian R; Thomas SK; Weber D; Kaufman JL; Harvey RD; Walker D -
Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis
Volume: 118 Page(s): 822 - 822
11/18/2011 Authors: Harvey RD; Jacobus SJ; Rajkumar SV; Greipp PR; Lonial S -
A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Volume: 118 Page(s): 141 - 142
11/18/2011 Authors: Lonial S; Jakubowiak AJ; Jagannath S; Raab MS; Facon T; Vij R; Moreau P; Reece DE; White DJ; Benboubker L -
The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
Volume: 118 Page(s): 1709 - 1710
11/18/2011 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Langston A; Steuer CE; Flowers CR; Boise LH; Lonial S -
Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 2-3 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study
Volume: 118 Page(s): 1697 - 1698
11/18/2011 Authors: Jagannath S; Lonial S; Jakubowiak AJ; Facon T; Vij R; Raab MS; White DJ; Wang M-H; Parli T; Bartlett BJ -
Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study
Volume: 118 Page(s): 140 - 140
11/18/2011 Authors: Richardson PG; Baz R; Wang L; Jakubowiak AJ; Berg D; Liu G; Gupta N; Di Bacco A; Hui A-M; Lonial S -
Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2)
Volume: 118 Page(s): 370 - 371
11/18/2011 Authors: Richardson PG; Alsina M; Weber DM; Coutre SE; Lonial S; Gasparetto C; Warsi G; Ondovik M; Mukhopadhyay S; Snodgrass S -
Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis
Volume: 118 Page(s): 807 - 808
11/18/2011 Authors: Nooka AK; Behera M; Boise LH; Watson M; Kaufman JL; Lonial S -
Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis
Volume: 118 Page(s): 855 - 856
11/18/2011 Authors: Prichard JM; Muppidi S; Flowers CR; Kaufman JL; Lechowicz MJ; Lonial S; Nooka AK; Sinha R; Waller EK; Langston A -
A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
BLOOD Volume: 118 Page(s): 1691 - 1691
11/18/2011 Authors: Nooka AK; Muppidi S; Harvey RD; Kaufman JL; Langston A; Lewis C; Boise LH; Flowers CR; Lonial S -
Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial
Volume: 118 Page(s): 368 - 369
11/18/2011 Authors: Dimopoulos MA; Jagannath S; Yoon S-S; Siegel DS; Lonial S; Hajek R; Facon T; Rosinol L; Blacklock HA; Goldschmidt H -
The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM)
Volume: 118 Page(s): 1266 - 1266
11/18/2011 Authors: Lonial S; Cohen A; Zonder J; Benzinger WI; Kaufman JL; Orlowski RZ; Harvey RD; Alexanian R; Thomas SK; Weber D -
Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1
Volume: 118 Page(s): 1701 - 1702
11/18/2011 Authors: San-Miguel JF; de Moraes Hungria VT; Yoon S-S; Wiktor-Jedrzejczak W; Elghandour A; Siritanaratkul N; Dimopoulos MA; Corradini P; Nakorn TN; Shelekhova T -
Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
Volume: 118 Page(s): 290 - 291
11/18/2011 Authors: Richardson PG; Siegel DS; Vij R; Hofmeister CC; Jagannath S; Chen C; Lonial S; Jakubowiak AJ; Bahlis NJ; Baz R -
Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT)
Volume: 118 Page(s): 375 - 375
11/18/2011 Authors: Freytes CO; Vesole DH; Zhong X; Le-Rademacher J; Dispenzieri A; Lonial S; Milone G; Hari P -
Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes
Volume: 118 Page(s): 603 - 603
11/18/2011 Authors: Mulligan G; Lichter DI; Di Bacco A; Blakemore SJ; Berger A; Koenig E; Bernard H; Trepicchio WL; Li B; Lonial S -
Validation of the Function of 14-3-3 zeta in Multiple Myeloma (MM)
Volume: 118 Page(s): 600 - 601
11/18/2011 Authors: Gu Y; Kaufman JL; Boise LH; Lonial S -
Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor
Volume: 118 Page(s): 1689 - 1689
11/18/2011 Authors: Matulis SM; Kaufman JL; Lonial S; Boise LH -
Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial
Volume: 118 Page(s): 371 - 371
11/18/2011 Authors: Richardson PG; Wolf JL; Jakubowiak AJ; Zonder JA; Lonial S; Irwin D; Densmore J; Krishnan A; Raje NS; Bar MH -
Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
Volume: 118 Page(s): 707 - 708
11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT -
Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial
Volume: 118 Page(s): 1287 - 1288
11/18/2011 Authors: Harvey RD; Lonial S; Renfroe H; Sinha R; Flowers CR; Lechowicz MJ; Khoury HJ; Langston A; Waller EK; Kaufman JL -
MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells
Volume: 118 Page(s): 815 - 816
11/18/2011 Authors: Gu Y; Kaufman JL; Boise LH; Lonial S -
ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma
Volume: 118 Page(s): 1244 - 1245
11/18/2011 Authors: Kim S-J; Moreno CS; Lonial S; Boise LH -
Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) - a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR)
Volume: 118 Page(s): 236 - 236
11/18/2011 Authors: Saad AA; Vesole DH; Le-Rademacher J; Zhong X; Dispenzieri A; Lonial S; Milone GA; Hari P -
Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Volume: 118 Page(s): 1693 - 1693
11/18/2011 Authors: Kurzrock R; Voorhees PM; Casper C; Furman RR; Fayad L; Lonial S; Borghaei H; Jagannath S; Sokol L; Usmani S -
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Oncology (Williston Park) Volume: 25 Suppl 2 Page(s): 25 - 31
11/15/2011 Authors: Lonial S; Boise LH -
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
J Clin Oncol Volume: 29 Page(s): 4243 - 4249
11/10/2011 Authors: Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M -
Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 379 - 384
10/01/2011 Authors: Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR -
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Transfusion Volume: 51 Page(s): 2175 - 2182
10/01/2011 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C -
Monoclonal antibodies in the treatment of multiple myeloma.
Br J Haematol Volume: 154 Page(s): 745 - 754
09/01/2011 Authors: Richardson PG; Lonial S; Jakubowiak AJ; Harousseau J-L; Anderson KC -
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.
Blood Volume: 118 Page(s): 1979 - 1988
08/18/2011 Authors: Kumar S; Zhang M-J; Li P; Dispenzieri A; Milone GA; Lonial S; Krishnan A; Maiolino A; Wirk B; Weiss B -
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.
Blood Volume: 118 Page(s): 1329 - 1339
08/04/2011 Authors: Morales AA; Kurtoglu M; Matulis SM; Liu J; Siefker D; Gutman DM; Kaufman JL; Lee KP; Lonial S; Boise LH -
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
Transfusion Volume: 51 Page(s): 1779 - 1783
08/01/2011 Authors: Renfroe H; Arnold M; Vaughn L; Harvey RD; Hamilton E; Lonial S; Khoury HJ; Kaufman JL; Lechowicz MJ; Flowers CR -
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
Blood Volume: 118 Page(s): 535 - 543
07/21/2011 Authors: Jakubowiak AJ; Griffith KA; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje NS -
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Blood Volume: 117 Page(s): 6063 - 6073
06/09/2011 Authors: Cavo M; Rajkumar SV; Palumbo A; Moreau P; Orlowski R; Blad J; Sezer O; Ludwig H; Dimopoulos MA; Attal M -
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
Eur J Haematol Volume: 86 Page(s): 484 - 487
06/01/2011 Authors: Zangari M; Aujay M; Zhan F; Hetherington KL; Berno T; Vij R; Jagannath S; Siegel D; Keith Stewart A; Wang L -
LONG-TERM FOLLOW-UP IN PX-171-003-A1, AN OPEN-LABEL, SINGLE-ARM PHASE (PH) 2 STUDY OF CARFILZOMIB (CFZ) IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM): ANALYSIS BY SUBGROUPS OF INTEREST
Volume: 22 Page(s): 200 - 200
06/01/2011 Authors: Siegel DS; Martin T; Wang M; Vij R; Jakubowiak AJ; Lonial S; Kukreti V; Alsina M; Somlo G; Kunkel L -
Is subcutaneous bortezomib ready for prime time?
Curr Hematol Malig Rep Volume: 6 Page(s): 73 - 74
06/01/2011 Authors: Lonial S -
High-risk multiple myeloma: does it still exist?
Volume: 11 Suppl 1 Page(s): S70 - S76
06/01/2011 Authors: Tuchman SA; Lonial S -
RESPONSES TO SINGLE-AGENT CARFILZOMIB (CFZ) ARE NOT AFFECTED BY CYTOGENETICS IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM)
Volume: 22 Page(s): 122 - 122
06/01/2011 Authors: Jakubowiak AJ; Martin T; Singhal S; Wang M; Vij R; Jagannath S; Lonial S; Kukreti V; Buadi F; Kunkel L -
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
Br J Haematol Volume: 153 Page(s): 729 - 740
06/01/2011 Authors: Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Alsina M; Albitar M; Berman D; Messina M; Anderson KC -
PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma.
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: San-Miguel JF; Lonial S; Hungria V; Moreau P; Einsele H; Lee JH; Yoon S; Corradini P; Jedrzejczak WW; Tan DC -
PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis
JOURNAL OF CLINICAL ONCOLOGY Volume: 29
05/20/2011 Authors: Siegel DSD; Martin T; Wang M; Vij R; Lonial S; Kukreti V; Bahlis NJ; Alsina M; Somlo G; Buadi F -
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
Blood Volume: 117 Page(s): 4691 - 4695
05/05/2011 Authors: Rajkumar SV; Harousseau J-L; Durie B; Anderson KC; Dimopoulos M; Kyle R; Blade J; Richardson P; Orlowski R; Siegel D -
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through JNK-dependent downregulation of c-FLIP in head and neck cancer cells
Volume: 71
04/15/2011 Authors: Zhao L; Yue P; Lonial S; Khuri FR; Sun S-Y -
Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons.
Autophagy Volume: 7 Page(s): 448 - 449
04/01/2011 Authors: Lonial S; Boise LH -
Initial genome sequencing and analysis of multiple myeloma.
Nature Volume: 471 Page(s): 467 - 472
03/24/2011 Authors: Chapman MA; Lawrence MS; Keats JJ; Cibulskis K; Sougnez C; Schinzel AC; Harview CL; Brunet J-P; Ahmann GJ; Adli M -
Treatment options for relapsed and refractory multiple myeloma.
Clin Cancer Res Volume: 17 Page(s): 1264 - 1277
03/15/2011 Authors: Lonial S; Mitsiades CS; Richardson PG -
Putting the E (evidence) in a new Era for myeloma.
Leuk Lymphoma Volume: 52 Page(s): 349 - 350
03/01/2011 Authors: Kaufman JL; Lonial S -
Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes.
Leukemia Volume: 25 Page(s): 362 - 365
02/01/2011 Authors: Giver CR; Jaye DL; Waller EK; Kaufman JL; Lonial S -
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
Br J Haematol Volume: 152 Page(s): 367 - 379
02/01/2011 Authors: Richardson PG; Mitsiades CS; Laubach JP; Lonial S; Chanan-Khan AA; Anderson KC -
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.
Cancer Chemother Pharmacol Volume: 67 Page(s): 57 - 67
01/01/2011 Authors: Reece DE; Sullivan D; Lonial S; Mohrbacher AF; Chatta G; Shustik C; Burris H; Venkatakrishnan K; Neuwirth R; Riordan WJ -
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
Blood Volume: 116 Page(s): 5285 - 5288
12/09/2010 Authors: David E; Kaufman JL; Flowers CR; Schafer-Hales K; Torre C; Chen J; Marcus AI; Sun S-Y; Boise LH; Lonial S -
Up-Front Management of Multiple Myeloma
ONCOLOGY-NEW YORK Volume: 24 Page(s): 8 - 14
12/01/2010 Authors: Lonial S; Anderson KC; Fonseca R; Love N -
A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma
Volume: 116 Page(s): 817 - 817
11/19/2010 Authors: Shah JJ; Zonder JA; Cohen A; Weter D; Thomas S; Wang M; Kaufman JL; Burt SM; Walker D; Freeman B -
Cost-Effectiveness Analysis of a "Just-In-Time" Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant.
Volume: 116 Page(s): 923 - 924
11/19/2010 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Repfroe H; Kaufman JL; Lonial S; Flowers CR; Lechowicz MJ; Langston A -
Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study.
Volume: 116 Page(s): 1251 - 1251
11/19/2010 Authors: Kaufman JL; Shah JJ; Laubach JP; Heffner L; Francis D; Harvey RD; Lewis C; Tighiouart M; Richardson P; Orlowski RZ -
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial
Volume: 116 Page(s): 806 - 806
11/19/2010 Authors: Jakubowiak AJ; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach JP; Raje N; Anderson TB -
Distribution of Bim Determines MCL-1 Dependence or Co-Dependence on BCL-x(L)/BCL-2 In Multiple Myeloma.
Volume: 116 Page(s): 1652 - 1652
11/19/2010 Authors: Boise LH; Morales AA; Kurtoglu M; Matulis SM; Markovitz R; Lee KP; Lonial S -
Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth
Volume: 116 Page(s): 1294 - 1294
11/19/2010 Authors: Hitosugi T; Kang S; Vander Heiden M; Chung T-W; Elf S; Lythgoe K; Dong S; Lonial S; Wang X; Chen G -
Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
Volume: 116 Page(s): 805 - 806
11/19/2010 Authors: Lonial S; Vij R; Harousseau J-L; Facon T; Moreau P; Leleu X; Mazumder A; Kaufman JL; Westland CE; Tsao C -
Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma
Volume: 116 Page(s): 1155 - 1155
11/19/2010 Authors: Shah JJ; Harvey RD; O'Connor OA; Jakubowiak AJ; Smith MR; Orlowski RZ; Mulligan GJ; Smith PG; Pickard MD; Dezube BJ -
High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)
Volume: 116 Page(s): 582 - 582
11/19/2010 Authors: Rodriguez TE; Stiff PJ; Smith SE; Kaufman JL; Lee M; Parthasarathy M; Earley ZM; Lonial S; Vesole DH -
Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
Volume: 116 Page(s): 434 - 434
11/19/2010 Authors: Richardson PG; Moreau P; Jakubowiak AJ; Facon T; Jagannath S; Vij R; Reece DE; White DJ; Raab MS; Benboubker L -
Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
Volume: 116 Page(s): 814 - 815
11/19/2010 Authors: Singhal SB; Siegel DSD; Martin T; Vij R; Wang M; Jakubowiak AJ; Lonial S; Kukreti V; Zonder JA; Wong AF -
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After > 2 Years of Follow-up
Volume: 116 Page(s): 1257 - 1257
11/19/2010 Authors: Richardson PG; Jagannath S; Jakubowiak AJ; Lonial S; Raje N; Alsina M; Ghobrial I; Schlossman RL; Mazumder A; Munshi NC -
Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle
Volume: 116 Page(s): 819 - 820
11/19/2010 Authors: Raibagkar PS; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S -
Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program
Volume: 116 Page(s): 813 - 814
11/19/2010 Authors: Siegel DS; Jagannath S; Hajek R; Dimopoulos MA; Yoon S-S; Lonial S; Laubach JP; Graef T; Pietrangelo D; Lupinacci L -
Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM).
Volume: 116 Page(s): 1249 - 1250
11/19/2010 Authors: Martin T; Singhal SB; Vij R; Wang M; Keith-Stewart A; Jagannath S; Lonial S; Jakubowiak AJ; Kukreti V; Bahlis NJ -
The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics
Volume: 116 Page(s): 1555 - 1556
11/19/2010 Authors: Wear S; Richardson PG; Revta C; Vij R; Fiala M; Lonial S; Francis D; diCapua Siegel DS; Schramm A; Jakubowiak AJ -
Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
Volume: 116 Page(s): 433 - 433
11/19/2010 Authors: Samuel D; Martin T; Wang M; Vij R; Jakubowiak AJ; Jagannath S; Lonial S; Kukreti V; Bahlis NJ; Alsina M -
Lenalidomide (LEN) Therapy In Combination with Dexamethasone (DEX) Is Associated with a Low Incidence of Viral Infections
Volume: 116 Page(s): 812 - 813
11/19/2010 Authors: Baz R; Lonial S; Hussein M; Swern AS; Dimopoulos MA -
Tolerance and Response to Initial Systemic Therapy In Older Patients with Multiple Myeloma (MM): Observations From 276 Unselected Recent Cases In the Practices of US-Based Medical Oncologists (MOs).
Volume: 116 Page(s): 645 - 645
11/19/2010 Authors: Love N; Lonial S; Anderson KC; Fonseca R; Elder M; Paley D; Ziel K -
Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib
Volume: 116 Page(s): 809 - 809
11/19/2010 Authors: Jakubowiak AJ; Martin T; Singhal SB; Wang M; Vij R; Jagannath S; Lonial S; Kukreti V; Buadi F; Bray L -
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.
Transfusion Volume: 50 Page(s): 2424 - 2431
11/01/2010 Authors: Akhtari M; Giver CR; Ali Z; Flowers CR; Gleason CL; Hillyer CD; Kaufman J; Khoury HJ; Langston AA; Lechowicz MJ -
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD -
Melphalan or no melphalan: that is the question.
Oncology (Williston Park) Volume: 24 Page(s): 1000 - 1001
10/01/2010 Authors: Kaufman J; Lonial S -
Melphalan or No Melphalan: That Is the Question KAUFMAN ARTICLE REVIEWED
ONCOLOGY-NEW YORK Volume: 24 Page(s): 1000 - 1001
10/01/2010 Authors: Kaufman J; Lonial S -
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Leuk Res Volume: 34 Page(s): 1111 - 1118
09/01/2010 Authors: Jagannath S; Dimopoulos MA; Lonial S -
The White House crusade against ... MGUS?
Blood Volume: 116 Page(s): 1020 - 1021
08/19/2010 Authors: Lonial S -
Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.
J Clin Oncol Volume: 28 Page(s): 3701 - 3708
08/10/2010 Authors: van Rhee F; Fayad L; Voorhees P; Furman R; Lonial S; Borghaei H; Sokol L; Crawford J; Cornfeld M; Qi M -
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Blood Volume: 116 Page(s): 679 - 686
08/05/2010 Authors: Richardson PG; Weller E; Lonial S; Jakubowiak AJ; Jagannath S; Raje NS; Avigan DE; Xie W; Ghobrial IM; Schlossman RL -
Monoclonal gammopathy of undetermined significance: a consensus statement.
Br J Haematol Volume: 150 Page(s): 28 - 38
07/01/2010 Authors: Berenson JR; Anderson KC; Audell RA; Boccia RV; Coleman M; Dimopoulos MA; Drake MT; Fonseca R; Harousseau J-L; Joshua D -
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Cancer Volume: 116 Page(s): 3143 - 3151
07/01/2010 Authors: Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S -
Improving induction therapy in multiple myeloma.
Curr Hematol Malig Rep Volume: 5 Page(s): 119 - 128
07/01/2010 Authors: Nooka A; Gleason C; Lonial S -
MLN4924, A NOVEL NAE INHIBITOR IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND NON-HODGKIN'S LYMPHOMA (NHL): PHASE 1 DOSE-ESCALATION STUDY
Volume: 95 Page(s): 160 - 160
06/15/2010 Authors: Shah J; Jakubowiak A; O'Connor O; Orlowski R; Patterson M; Harvey D; Berger A; McDonald A; Mulligan G; Boral A -
ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
Volume: 95 Page(s): 157 - 158
06/15/2010 Authors: Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman J; Leleu X; Tsao C; Fry J -
INTERIM ANALYSIS OF A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF VORINOSTAT OR PLACEBO COMBINED WITH BORTEZOMIB IN RELAPSED MULTPLE MYELOMA
Volume: 95 Page(s): 156 - 156
06/15/2010 Authors: Jagannath S; Siegel D; Hajek R; Dimopoulos M; Yoon SS; Lonial S; Graef T; Lupinacci L; Reiser D; Anderson K -
A PHASE IB STUDY EVALUATING THE COMBINATION OF ORAL PANOBINOSTAT (LBH589) WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Volume: 95 Page(s): 158 - 158
06/15/2010 Authors: Mateos MV; Spencer A; Taylor K; Lonial S; De La Rubia J; Facon T; Bengoudifa R; Klebsattel M; Hazell K; Bourquelot P -
CARFILZOMIB, A NOVEL PROTEASOME INHIBITOR, EXHIBITS MINIMAL NEUROTOXIC AND PERIPHERAL NEUROPATHIC EFFECTS IN PRECLINICAL AND CLINICAL STUDIES
Volume: 95 Page(s): 159 - 160
06/15/2010 Authors: Lonial S; Jagannath S; Martin T; Wang M; Singhal S; Trudel S; Le M; Kirk C; Arastu-Kapur S; Vij R -
COMBINED VORINOSTAT AND BORTEZOMIB IN BORTEZOMIB-REFRACTORY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INTERIM ANALYSIS OF A PHASE IIB STUDY
Volume: 95 Page(s): 156 - 157
06/15/2010 Authors: Siegel D; Jagannath S; Lonial S; Dimopoulos M; Yoon SS; Graef T; Pietrangelo D; Lupinacci L; Reiser D; Anderson K -
Future directions in immunomodulatory therapy.
Med Oncol Volume: 27 Suppl 1 Page(s): S62 - S66
06/01/2010 Authors: Lonial S -
MLN4924, A NOVEL NAE INHIBITOR IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND NON-HODGKIN'S LYMPHOMA (NHL): PHASE 1 DOSE-ESCALATION STUDY
Volume: 95 Page(s): 160 - 160
06/01/2010 Authors: Shah J; Jakubowiak A; O'Connor O; Orlowski R; Patterson M; Harvey D; Berger A; McDonald A; Mulligan G; Boral A -
CARFILZOMIB, A NOVEL PROTEASOME INHIBITOR, EXHIBITS MINIMAL NEUROTOXIC AND PERIPHERAL NEUROPATHIC EFFECTS IN PRECLINICAL AND CLINICAL STUDIES
Volume: 95 Page(s): 159 - 160
06/01/2010 Authors: Lonial S; Jagannath S; Martin T; Wang M; Singhal S; Trudel S; Le M; Kirk C; Arastu-Kapur S; Vij R -
ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
Volume: 95 Page(s): 157 - 158
06/01/2010 Authors: Lonial S; Vij R; Harousseau JL; Facon T; Moreau P; Mazumder A; Kaufman J; Leleu X; Tsao C; Fry J -
A PHASE IB STUDY EVALUATING THE COMBINATION OF ORAL PANOBINOSTAT (LBH589) WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Volume: 95 Page(s): 158 - 158
06/01/2010 Authors: Mateos MV; Spencer A; Taylor K; Lonial S; De la Rubia J; Facon T; Bengoudifa R; Klebsattel M; Hazell K; Bourquelot P -
INTERIM ANALYSIS OF A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF VORINOSTAT OR PLACEBO COMBINED WITH BORTEZOMIB IN RELAPSED MULTPLE MYELOMA
Volume: 95 Page(s): 156 - 156
06/01/2010 Authors: Jagannath S; Siegel D; Hajek R; Dimopoulos M; Yoon SS; Lonial S; Graef T; Lupinacci L; Reiser D; Anderson K -
COMBINED VORINOSTAT AND BORTEZOMIB IN BORTEZOMIB-REFRACTORY PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INTERIM ANALYSIS OF A PHASE IIB STUDY
Volume: 95 Page(s): 156 - 157
06/01/2010 Authors: Siegel D; Jagannath S; Lonial S; Dimopoulos M; Yoon SS; Graef T; Pitrangelo D; Lupinacci L; Reiser D; Anderson K -
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
J Biol Chem Volume: 285 Page(s): 16096 - 16104
05/21/2010 Authors: Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun S-Y -
Update on vantage program to assess combined vorinostol (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM)
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Jagannath S; Siegel DS; Hajek R; Dimopoulos MA; Yoon S; Lonial S; Graef T; Lupinacci L; Reiser D; Anderson KC -
Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM)
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Shah JJ; Cohen AD; Zonder JA; Kaufman JL; Burt SM; Freeman BB; Rush S; Ptaszynski AM; Orlowski RZ; Lonial S -
Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Harvey RD; Kauh JS; Ramalingam SS; Lewis CM; Chen Z; Lonial S; Blount IC; Shin DM; Khuri FR; Owanikoko TK -
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Lonial S; Vij R; Harousseau J; Facon T; Moreau P; Leleu X; Westland C; Singhal AK; Jagannath S -
Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Anderson KC; Weller E; Lonial S; Jakubowiak AJ; Jagannath S; Raje NS; Avigan D; Knight RD; Esseltine D; Richardson PG -
PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM)
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Alsina M; Lonial S; Weber DM; Coutre SE; Kang BP; Glynos T; Warsi G; Snodgrass SM; Richardson PG -
Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasoine inhibitor (PI)
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Wolf JL; Vij R; Lonial S; Wang M; Jagannath S; Singhal S; Le MH; Kirk C; Arastu-Kapur S; Siegel DS -
Does the magnitude of response to initial induction therapy impact plans for immediate autologons stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)?
JOURNAL OF CLINICAL ONCOLOGY Volume: 28
05/20/2010 Authors: Willey J; Lemke KE; Williams ME; Green MR; Lonial S -
Presentation and risk stratification--improving prognosis for patients with multiple myeloma.
Cancer Treat Rev Volume: 36 Suppl 2 Page(s): S12 - S17
05/01/2010 Authors: Lonial S -
Frontline regimens for multiple myeloma patients.
Clin Adv Hematol Oncol Volume: 8 Page(s): 331 - 332
05/01/2010 Authors: Lonial S -
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
Mayo Clin Proc Volume: 85 Page(s): 197 - 199
02/01/2010 Authors: Fonseca R; Richardson P; Giralt S; Lonial S; Rajkumar SV; Stewart AK; Bensinger W; Somlo G; Vescio R; Mikhael J -
Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.
Hematology Am Soc Hematol Educ Program Volume: 2010 Page(s): 310 - 313
01/01/2010 Authors: Shah N; Lonial S -
Relapsed multiple myeloma.
Hematology Am Soc Hematol Educ Program Volume: 2010 Page(s): 303 - 309
01/01/2010 Authors: Lonial S -
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
Cancer Res Volume: 69 Page(s): 8967 - 8976
12/01/2009 Authors: Fu L; Kim Y-A; Wang X; Wu X; Yue P; Lonial S; Khuri FR; Sun S-Y -
Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).
Volume: 114 Page(s): 725 - 726
11/20/2009 Authors: Jakubowiak A; Wang L; Orlowski RZ; Jagannath S; Siegel D; Stewart AK; Kukreti V; Lonial S; McDonagh KT; Vallone M -
Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects
Volume: 114 Page(s): 178 - 179
11/20/2009 Authors: Vij R; Wang L; Orlowski RZ; Stewart AK; Jagannath S; Lonial S; Trudel S; Jakubowiak AJ; Belch A; Alsina M -
Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Volume: 114 Page(s): 1151 - 1152
11/20/2009 Authors: Muringampurath-John D; Flowers CR; Jabbar AA; Sinha R; Arellano M; Bernal-Mizrachi L; Kaufman JL; Jaye DL; Chen Z; Lechowicz MJ -
Tanespimycin plus Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study
Volume: 114 Page(s): 1128 - 1129
11/20/2009 Authors: Richardson PG; Chanan-Khan AA; Lonial S; Krishnan AY; Carroll MP; Albitar M; Kopit J; Berman D; Anderson KC -
Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.
Volume: 114 Page(s): 1497 - 1497
11/20/2009 Authors: Siegel D; Jagannath S; Lonial S; Dimopoulos MA; Graef T; Pietrangelo D; Lupinacci L; Reiser D; Rizvi S; Anderson KC -
The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma.
Volume: 114 Page(s): 573 - 574
11/20/2009 Authors: Love N; Lonial S; Ziel K; Paley D; Elder M; Asnis-Alibozek A -
The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.
Volume: 114 Page(s): 673 - 673
11/20/2009 Authors: Deshpande SS; Lechowicz MJ; Sinha R; Kaufman JL; Boise LH; Lonial S; Flowers CR -
High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.
Volume: 114 Page(s): 501 - 502
11/20/2009 Authors: Richardson PG; Lonial S; Jakubowiak AJ; Jagannath S; Raje NS; Avigan DE; Ghobrial I; Schlossman RL; Mazumder A; Munshi NC -
Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis
Volume: 114 Page(s): 27 - 28
11/20/2009 Authors: Hari PN; Barrett AJ; Shrestha S; da Silva GT; Zhang M-J; Dispenzieri A; Milone GA; Lonial S; Ringden O -
Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience
Volume: 114 Page(s): 222 - 222
11/20/2009 Authors: Mahindra A; Vesole D; Kalaycio ME; Vela-Ojeda J; Shrestha S; Zhang M-J; Dispenzieri A; Milone GA; Lonial S; Hari PN -
Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor
Volume: 114 Page(s): 1425 - 1425
11/20/2009 Authors: Whittaker S; Kim EJ; Prince M; Demierre MF; Giver C; Lonial S; Pickarz R; Kim YH; Nichols J; Nix D -
Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma
Volume: 114 Page(s): 1118 - 1119
11/20/2009 Authors: Zangari M; Polavaram L; Zhan F; Tricot GJ; Vij R; Jagannath S; Siegel D; Stewart AK; Wang L; Orlowski RZ -
The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated
BLOOD Volume: 114 Page(s): 1432 - 1432
11/20/2009 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Lonial S; Flowers CR -
Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience.
Volume: 114 Page(s): 1496 - 1496
11/20/2009 Authors: Nooka AK; Kaufman JL; Heffner LT; Gleason CL; Lonial S -
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial
Volume: 114 Page(s): 60 - 60
11/20/2009 Authors: Jakubowiak AJ; Reece DE; Hofmeister CC; Lonial S; Zimmerman TM; Campagnaro EL; Schlossman RL; Laubach J; Raje N; Anderson T -
Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma
Volume: 114 Page(s): 1492 - 1493
11/20/2009 Authors: Lonial S; Harvey RD; Francis D; Gul E; Jagannath S; Farag S; Hoth D; Frumento R; Garlich JR; Trudel S -
A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.
Volume: 114 Page(s): 1481 - 1481
11/20/2009 Authors: Lonial S; Francis D; Karanes C; Trudel S; Dollard AM; Aceo F; Gul E; Kakar S; Krishnan AY; Reece DE -
Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results
Volume: 114 Page(s): 741 - 742
11/20/2009 Authors: Richardson P; Wolf JL; Jakubowiak A; Zonder JA; Lonial S; Irwin DH; Krishnan A; Densmore J; Raje N; Bar MH -
Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? A CIBMTR Analysis From 1989-2005
Volume: 114 Page(s): 28 - 29
11/20/2009 Authors: Kumar S; Shrestha S; Zhang M-J; Dispenzieri A; Milone GA; Lonial S; Hari PN -
Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone.
Volume: 114 Page(s): 1124 - 1125
11/20/2009 Authors: Lonial S; Baz R; Swern AS; Weber D; Dimopoulos MA -
Inhibition of the Proteasome in Bone Marrow-Derived CD138+Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients
Volume: 114 Page(s): 732 - 732
11/20/2009 Authors: Trudel S; Lee S; Kirk CJ; Gabrail N; Lonial S; Wang L; Orlowski RZ; Kukreti V; Stewart AK; Jagannath S -
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.
Sci Signal Volume: 2 Page(s): ra73
11/17/2009 Authors: Hitosugi T; Kang S; Vander Heiden MG; Chung T-W; Elf S; Lythgoe K; Dong S; Lonial S; Wang X; Chen GZ -
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
Leukemia Volume: 23 Page(s): 1939 - 1940
11/01/2009 Authors: Harvey RD; Nettles J; Wang B; Sun S-Y; Lonial S -
Supportive therapies in multiple myeloma.
J Natl Compr Canc Netw Volume: 7 Page(s): 971 - 979
10/01/2009 Authors: Gleason C; Nooka A; Lonial S -
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
Leukemia Volume: 23 Page(s): 1904 - 1912
10/01/2009 Authors: Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Kumar S; Munshi NC; Dispenzieri A; Kyle R -
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
Leukemia Volume: 23 Page(s): 1716 - 1730
10/01/2009 Authors: Palumbo A; Sezer O; Kyle R; Miguel JS; Orlowski RZ; Moreau P; Niesvizky R; Morgan G; Comenzo R; Sonneveld P -
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Blood Volume: 114 Page(s): 1729 - 1735
08/27/2009 Authors: Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R -
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
J Clin Oncol Volume: 27 Page(s): 3518 - 3525
07/20/2009 Authors: Richardson PG; Xie W; Mitsiades C; Chanan-Khan AA; Lonial S; Hassoun H; Avigan DE; Oaklander AL; Kuter DJ; Wen PY -
Risky business in myeloma.
Blood Volume: 114 Page(s): 496 - 497
07/16/2009 Authors: Lonial S -
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease.
Am Heart J Volume: 158 Page(s): 53 - 60.e1
07/01/2009 Authors: Subramaniyam V; Waller EK; Murrow JR; Manatunga A; Lonial S; Kasirajan K; Sutcliffe D; Harris W; Taylor WR; Alexander RW -
TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
Volume: 94 Page(s): 152 - 153
06/07/2009 Authors: Richardson PG; Chanan-Khan A; Lonial S; Krishnan A; Carroll M; Alsina M; Albitar M; Berman D; Szatrowski T; Kaplita S -
SAFETY AND EFFICACY UPDATE OF PX-171-004, AN OPEN-LABEL PHASE II TRIAL OF CARFILZOMIB IN RELAPSED MULTIPLE MYELOMA
Volume: 94 Page(s): 191 - 191
06/07/2009 Authors: Siegel D; Wang M; Stewart K; Jakubowiak A; Jagannath S; McDonagh K; Kukreti V; Lonial S; Le MH; Cruickshank S -
TANESPIMYCIN AND BORTEZOMIB IN PATIENTS WITH RELAPSED AND RELAPSED AND REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS OF A PHASE 1/2 STUDY
Volume: 94 Page(s): 152 - 153
06/01/2009 Authors: Richardson PG; Chanan-Khan A; Lonial S; Krishnan A; Carroll M; Alsina M; Albitar M; Berman D; Szatrowski T; Kaplita S -
SAFETY AND EFFICACY UPDATE OF PX-171-004, AN OPEN-LABEL PHASE II TRIAL OF CARFILZOMIB IN RELAPSED MULTIPLE MYELOMA
Volume: 94 Page(s): 191 - 191
06/01/2009 Authors: Siegel D; Wang M; Stewart K; Jakubowiak A; Jagannath S; McDonagh K; Kukreti V; Lonial S; Cruickshank S; Vij R -
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.
Br J Haematol Volume: 145 Page(s): 681 - 708
06/01/2009 Authors: Lonial S; Cavenagh J -
Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study
Volume: 27
05/20/2009 Authors: Richardson PG; Chanan-Khan A; Lonial S; Krishnan A; Carroll M; Alsina M; Albitar M; Berman D; Kaplita S; Anderson K -
A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma.
J Clin Oncol Volume: 27 Page(s): 8597
05/20/2009 Authors: Lonial S; Francis D; Karanes C; Trudel S; Dollard A; Harvey D; Kaufman J -
Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study
Volume: 27
05/20/2009 Authors: Anderson KC; Jagannath S; Jakubowiak A; Lonial S; Raje N; Alsina M; Ghobrial I; Knight R; Esseltine D; Richardson P -
The HDAC inhibitor panobinostat (LBH589) induces transient thrombocytopenia in mice, with minimal effects on bone marrow megakaryocyte populations
Volume: 69
05/01/2009 Authors: Giver C; Waller E; Lonial S -
Treatment of multiple myeloma: whence truth over belief?
Oncology (Williston Park) Volume: 23 Page(s): 420 - 423
04/30/2009 Authors: Kaufman J; Lonial S -
Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation.
Mol Cell Biol Volume: 29 Page(s): 2105 - 2117
04/01/2009 Authors: Kang S; Elf S; Dong S; Hitosugi T; Lythgoe K; Guo A; Ruan H; Lonial S; Khoury HJ; Williams IR -
Treatment of Multiple Myeloma: Whence Truth Over Belief? The Kaufman article reviewed
ONCOLOGY-NEW YORK Volume: 23 Page(s): 420 - 423
04/01/2009 Authors: Kaufman J; Lonial S -
Treatment of relapsed and refractory myeloma.
Curr Hematol Malig Rep Volume: 4 Page(s): 99 - 107
04/01/2009 Authors: Kaufman J; Gleason C; Lonial S -
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Br J Haematol Volume: 144 Page(s): 895 - 903
03/01/2009 Authors: Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D -
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
Ann Oncol Volume: 20 Page(s): 520 - 525
03/01/2009 Authors: Goy A; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S -
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Leukemia Volume: 23 Page(s): 215 - 224
02/01/2009 Authors: Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S -
Panobinostat and Lenalidomide Combination Phase I Trial in Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S52 - S53
02/01/2009 Authors: Spencer A; Lonial S; Taylor K; Jalaluddin M; Hazell K; Bourquelot PM; San Miguel J -
Imipramine Blue, a Tricyclic Compound and an Inhibitor of NADPH Oxidase Induces G(2)/M Cell-Cycle Arrest
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S126 - S126
02/01/2009 Authors: David E; Lonial S; Kaufman JL; Arbiser J -
The research mission in myeloma.
Leukemia Volume: 23 Page(s): 422 - 423
02/01/2009 Authors: Richardson PG; San-Miguel J; Lonial S; Reece D; Jakubowiak A; Hussein M; Jagannath S; Mitsiades CS; Raje N; Kaufman J -
PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
Volume: 15 Page(s): 154 - 155
02/01/2009 Authors: Hutcherson DA; Surati M; Sanvidge K; Harvey D; Al-Baldawi RN; Langston A; Flowers C; Lonial S; Kaufman J; Lechowicz MJ -
SNS-032, a Potent and Selective CDK2, 7 and 9 Inhibitor, Demonstrates Preclinical Activity in Human Multiple Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S125 - S126
02/01/2009 Authors: David E; Lonial S; Taverna P; Stewart AK; Trudel S; Sebag M; Li Z; Shi C-X; Bergsagel PL; Chesi M -
Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S38 - S38
02/01/2009 Authors: Richardson PG; Lonial S; Jakubowiak A; Jagannath S; Raje N; Avigan D; Ghobrial IM; Schlossman R; Mazumder A; Munshi NC -
US Cooperative Group Trials
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S34 - S35
02/01/2009 Authors: Lonial S; Giralt S; Durie B; Barlogie B; Stadtmauer E; Anderson KC; Rajkumar SV -
Phase Ib Study of Elotuzumab (HuLuc63) in Combination with Lenalidomide in Relapsed Multiple Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S20 - S20
02/01/2009 Authors: Lonial S; Singhal A; Jagannath S; Vij R -
Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S38 - S38
02/01/2009 Authors: Richardson PG; Hideshima T; Jagannath S; Jakubowiak A; Lonial S; Raje N; Alsina M; Ghobrial IM; Schlossman R; Mazumder A -
A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S60 - S60
02/01/2009 Authors: Kaufman JL; Lonial S; Sinha R; Torre C; Langston AA; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT -
SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequen
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S127 - S127
02/01/2009 Authors: David E; Lonial S; Barwick B; Peng X; Kaufman J; Garlich J -
Phase I/II Trial of Perifosine plus Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib
CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S57 - S57
02/01/2009 Authors: Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M -
EXTRACORPOREAL PHOTOPHERESIS THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSE IS ASSOCIATED WITH CONTENT OF DENDRITIC CELLS AND T-CELLS IN PERIPHERAL BLOOD AT INITIATION OF TREATMENT
Volume: 15 Page(s): 128 - 129
02/01/2009 Authors: Akhtari M; Giver CR; Renfroe HM; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL -
The importance of complete response in outcomes in myeloma.
Cancer J Volume: 15 Page(s): 465 - 472
01/01/2009 Authors: Nooka A; Kaufman J; Lonial S -
A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
Volume: 112 Page(s): 1270 - 1270
11/16/2008 Authors: Lonial S; Francis D; Karanes C; Trudel S; Reece DE; Krishnan A; Buacharem M; Smith R; Zaman F; Gul E -
Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease
Volume: 112 Page(s): 432 - 432
11/16/2008 Authors: Giver CR; Akhtari M; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL; Vaughn ML -
CNTO 328, a Monoclonal Antibody to Interleukin-6. Is Active as a Single Agent in Castleman's Disease: Preliminary Results of a Phase I Study.
Volume: 112 Page(s): 371 - 371
11/16/2008 Authors: Van Rhee F; Fayad L; Voorhees P; Furiman RR; Borghaei H; Lonial S; Sokol L; Crawford J; Cornfield M; Qi M -
Patulin Acts Synergistically with Doxorubicin and Bortezomib in Cytotoxicity against Hematological Malignancies.
Volume: 112 Page(s): 921 - 921
11/16/2008 Authors: Hessel A; Tselanyane M; Wang F; David E; Lonial S; Waller EK -
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.
Volume: 112 Page(s): 614 - 615
11/16/2008 Authors: Richardson P; Jagannath S; Jakubowiak A; Lonial S; Raje N; Alsina M; Ghobrial I; Mazumder A; Munshi NC; Vesole DH -
Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status
Volume: 112 Page(s): 1268 - 1268
11/16/2008 Authors: Chanan-Khan A; Dimopoulos MA; Weber DM; Spencer A; Attal M; Belch A; Corso A; Fu T; Zeldis JB; Olesnyckyj M -
A Randomized Phase I Trial of Melphalan plus Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
Volume: 112 Page(s): 1144 - 1145
11/16/2008 Authors: Lonial S; Kaufman J; Torre C; Langston A; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT; Waller EK -
A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma.
Volume: 112 Page(s): 957 - 957
11/16/2008 Authors: Wolf JL; Siegel D; Matous J; Lonial S; Goldschmidt H; Schmitt S; Vij R; De Malgalhaes-Silverman M; Abonour R; Jalaluddin M -
A Phase I Study of CNTO 328, An Anti-Interelukin-6 Monoclonal Antibody in Patients with A-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.
Volume: 112 Page(s): 371 - 372
11/16/2008 Authors: Kurzrock R; Fayad L; Voorhees P; Furman RR; Lonial S; Borghaei H; Jagannath S; Sokol L; Cornfeld M; Qi M -
Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib
Volume: 112 Page(s): 321 - 322
11/16/2008 Authors: Richardson P; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin DH; Densmore J; Krishnan A; Raje N; Bar MH -
FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation
Volume: 112 Page(s): 1276 - 1276
11/16/2008 Authors: Kang S; Elf S; Dong S; Hitosugi T; Guo A; Ruan H; Lonial S; Khoury H; Williams I; Karsenty G -
Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
Volume: 112 Page(s): 1247 - 1247
11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R -
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study
Volume: 112 Page(s): 41 - 41
11/16/2008 Authors: Richardson P; Lonial S; Jakubowiak A; Jagannath S; Raje NS; Avigan D; Ghobrial IM; Schlossman RL; Mazumder A; Munshi NC -
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Volume: 26 Page(s): 4784 - 4790
10/10/2008 Authors: Chanan-Khan A; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D -
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Br J Haematol Volume: 143 Page(s): 222 - 229
10/01/2008 Authors: Lonial S; Richardson PG; San Miguel J; Sonneveld P; Schuster MW; Blad J; Cavenagh J; Rajkumar SV; Jakubowiak AJ; Esseltine D-L -
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP -
Regulation of alloimmune responses by dendritic cell subsets.
Exp Hematol Volume: 36 Page(s): 1309 - 1317
10/01/2008 Authors: Lonial S; Torre C; David E; Harris W; Arellano M; Waller EK -
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
Clin Cancer Res Volume: 14 Page(s): 5090 - 5098
08/15/2008 Authors: David E; Sinha R; Chen J; Sun S-Y; Kaufman JL; Lonial S -
Practical considerations for multiple myeloma: an overview of recent data and current options.
Clin Lymphoma Myeloma Volume: 8 Suppl 4 Page(s): S144 - S148
08/01/2008 Authors: Lonial S -
Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.
Leukemia Volume: 22 Page(s): 1280 - 1281
06/01/2008 Authors: Mazumder A; Kaufman J; Niesvizky R; Lonial S; Vesole D; Jagannath S -
Review of peripheral neuropathy in plasma cell disorders.
Hematol Oncol Volume: 26 Page(s): 55 - 65
06/01/2008 Authors: Silberman J; Lonial S -
The prognostic significance of donor dendritic cells in allogeneic hematopoietic progenitor cell transplant
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Dejoubner N; Ali Z; Grasier M; Hamilton E; Flowers C; Lonial S; Langston A; Waller EK -
Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Richardson PG; Lonial S; Jakubowiak A; Jagannath S; Raje N; Avigan D; Ghobrial IM; Knight R; Esseltine D; Anderson KC -
Research participants' views of nontherapeutic biopsies
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Pentz RD; Xu Z; Lonial S; Kauh JS; O'Regan RM; Waller EK; Shin DM; Fu H; Khuri F -
Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
JOURNAL OF CLINICAL ONCOLOGY Volume: 26
05/20/2008 Authors: Anderson KC; Jagannath S; Jakubowiak A; Lonial S; Raje N; Schlossman R; Munshi N; Knight R; Esseltine D; Richardson PG -
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Leukemia Volume: 22 Page(s): 842 - 849
04/01/2008 Authors: San-Miguel JF; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S -
Eliminating the complete response penalty from myeloma response assessment.
Blood Volume: 111 Page(s): 3297 - 3298
03/15/2008 Authors: Lonial S; Gertz MA -
Clinical uses of GM-CSF, a critical appraisal and update.
Biologics Volume: 2 Page(s): 13 - 27
03/01/2008 Authors: Arellano M; Lonial S -
Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070.
Leukemia Volume: 22 Page(s): 572 - 577
03/01/2008 Authors: Dong S; Kang S; Lonial S; Khoury HJ; Viallet J; Chen J -
Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.
J Biol Chem Volume: 283 Page(s): 4652 - 4657
02/22/2008 Authors: Kang S; Dong S; Guo A; Ruan H; Lonial S; Khoury HJ; Gu T-L; Chen J -
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options.
Clin Lymphoma Myeloma Volume: 8 Page(s): 52 - 54
02/01/2008 Authors: Gladney SP; Lonial S; Kaufman JL -
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Leukemia Volume: 22 Page(s): 414 - 423
02/01/2008 Authors: Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M -
The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma
Page(s): 309 - 322
01/01/2008 Authors: Harvey RD; Silberman J; Lonial S -
Maintenance Therapy in Multiple Myeloma
Page(s): 91 - 98
01/01/2008 Authors: Kaufman JL; Mihelic R; Lonial S -
PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
Future Oncol Volume: 3 Page(s): 639 - 647
12/01/2007 Authors: Harvey RD; Lonial S -
Multiple myeloma: novel approaches for relapsed disease.
Clin Lymphoma Myeloma Volume: 8 Suppl 1 Page(s): S18 - S23
12/01/2007 Authors: Lonial S -
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
N Engl J Med Volume: 357 Page(s): 2133 - 2142
11/22/2007 Authors: Weber DM; Chen C; Niesvizky R; Wang M; Belch A; Stadtmauer EA; Siegel D; Borrello I; Rajkumar SV; Chanan-Khan AA -
Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
Volume: 110 Page(s): 797A - 797A
11/16/2007 Authors: Richardson P; Jagannath S; Raje N; Jakubowiak A; Lonial S; Ghobrial I; Schlossman R; Mazumder A; Munshi N; Colson K -
Phase I/II report from a Multicenter trial of perifosine (KRX-0401) plus bortezomib in patients with relapsed or Relapsed/Refractory multiple myeloma previously treated with bortezomib
Volume: 110 Page(s): 354A - 355A
11/16/2007 Authors: Richardson P; Jakubowiak A; Wolf J; Allerton J; Zonder J; Lonial S; Krishnan A; Densmore J; Ghobrial I; Colson K -
Impact of prior lenalidomide treatment on peripheral blood stem cell (PBSC) mobilization in untreated multiple myeloma (MM) patients
Volume: 110 Page(s): 1057A - 1057A
11/16/2007 Authors: Mazumder A; Kaufman J; Lonial S; Jagannath S; Vesole D -
Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and BCl-2 inhibitor GX15-070
Volume: 110 Page(s): 858A - 859A
11/16/2007 Authors: Dong S; Kang S; Lonial S; Khoury HJ; Viallet J; Chen J -
Tanespimycin (T) plus bortezomib (BZ) in multiple myeloma (MM): Confirmation of the recommended dose using a novel formulation
Volume: 110 Page(s): 353A - 353A
11/16/2007 Authors: Richardson PG; Chanan-Khan A; Lonial S; Krishman A; Carroll M; Cropp GF; Kersey K; Abitar M; Johnson RG; Hannah AL -
Patulin, a mycotoxin, has potent cytotoxic activity on actue lymphoblastic leukemia and induce apoptosis through intrinsic and extrinsic pathways
Volume: 110 Page(s): 151B - 152B
11/16/2007 Authors: Wang F; David E; Lonial S; Arellano M; Khoury HJ; Langston A; Lechowicz MJ; Waller N -
A novel Pan-PI3K/Akt inhibitor, SF1126, inhibits in vitro growth of multiple myeloma cells
Volume: 110 Page(s): 275B - 275B
11/16/2007 Authors: Silberman J; Dalbey K; Torre C; David E; Bergsagel L; Durden D; Garlich J; Schwertschlag U; Lonial S -
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
Volume: 110 Page(s): 1055A - 1055A
11/16/2007 Authors: Kaufman JL; Gleason C; Heffner L; Lonial S -
A randomized phase I trial of Melphalan plus Bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
Volume: 110 Page(s): 288A - 289A
11/16/2007 Authors: Lonial S; Kaufman J; Langston A; Heffner LT; Torre C; Lechowicz MJ; Flowers C; McMillan S; Arnold M; Waller NK -
Combination of bortezomib with tipifarnib (R115777) induces synergistic myeloma cell apoptosis via down-regulation of HDAC6 and inhibition of aggresome formation
Volume: 110 Page(s): 455A - 455A
11/16/2007 Authors: David E; Schafer-Hales K; Marcus AI; Kaufman JL; Lonial S -
Therapeutic drug monitoring (TDM) of IV busulfan in patients with severe obesity
Volume: 110 Page(s): 592A - 592A
11/16/2007 Authors: Hutcherson DA; Sessions JK; Mihelic RA; Sanvidge K; Stricker SR; Langston A; Flowers C; Lechowicz MJ; Waller N; Lonial S -
The effect of rituximab on mobilization with AMD3100 plus G-CSF in patients with relapsed or refractory NHL or HD
Volume: 110 Page(s): 568A - 568A
11/16/2007 Authors: Kaufman JL; Cook AM; Flowers C; Langston AA; Lonial S; Lechowicz MJ; Khoury HJ; Calandra G; Waller N -
Durable responses with bortezomib in patients with relapsed or refractory Mantle Cell Lymphoma (MCL): Updated time-to-event analyses of the multicenter PINNACLE study
Volume: 110 Page(s): 45A - 45A
11/16/2007 Authors: Goy A; Bernstein S; Kahl B; Djulbegovic B; Robertson M; de Vos S; Epner E; Krishnan A; Leonard J; Lonial S -
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood Volume: 110 Page(s): 3557 - 3560
11/15/2007 Authors: Richardson PG; Sonneveld P; Schuster M; Irwin D; Stadtmauer E; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; Goldschmidt H -
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
Volume: 5 Page(s): 7 - 19
10/01/2007 Authors: Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M -
Complete remission of multiple myeloma.
Clin Adv Hematol Oncol Volume: 5 Page(s): 671 - 675
09/01/2007 Authors: Lonial S -
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
Cancer Cell Volume: 12 Page(s): 201 - 214
09/01/2007 Authors: Kang S; Dong S; Gu T-L; Guo A; Cohen MS; Lonial S; Khoury HJ; Fabbro D; Gilliland DG; Bergsagel PL -
Maintenance therapy in lymphoma.
Clin Lymphoma Myeloma Volume: 7 Page(s): 507 - 513
09/01/2007 Authors: Mihelic R; Kaufman J; Lonial S; Flowers C -
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
Mol Cancer Ther Volume: 6 Page(s): 2029 - 2038
07/01/2007 Authors: Elrod HA; Lin Y-D; Yue P; Wang X; Lonial S; Khuri FR; Sun S-Y -
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Blood Volume: 110 Page(s): 360 - 369
07/01/2007 Authors: Dong S; Kang S; Gu T-L; Kardar S; Fu H; Lonial S; Khoury HJ; Khuri F; Chen J -
Bortezomib in renally impaired multiple myeloma patients
Volume: 92 Page(s): 214 - 215
06/01/2007 Authors: Miguel JFS; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S -
Quality of response with bortezomib in APEX
Volume: 92 Page(s): 161 - 162
06/01/2007 Authors: Niesvizky R; Richardson PG; Rajkumar SV; Sonneveld P; Schuster MW; Coleman M; Irwin D; Stadtmauer EA; Facon T; Harousseau JL -
A multicenter phase I/II trial of perifosine (KRX-0401) + bortezomib in relapsed and refractory multiple myeloma patients previously treated wth bortezomib: Preliminary results
Volume: 92 Page(s): 155 - 156
06/01/2007 Authors: Richardson PG; Jakubowiak A; Wolf J; Krishnan A; Lonial S; Ghobrial I; Facon T; Colson K; Kendall T; Leister C -
Bortezomib,thalidomide and dexamethasone as induction
Volume: 92 Page(s): 181 - 181
06/01/2007 Authors: Kaufman JL; Gleason C; Heffner LT; Langston AA; Waller EK; Lonial S -
Next steps in myeloma management - The Ghobria/Ghobrial/Mitsiades et at article reviewed
ONCOLOGY-NEW YORK Volume: 21 Page(s): 798 - 799
06/01/2007 Authors: Lonial S -
Maintenance therapy in multiple myeloma.
Leukemia Volume: 21 Page(s): 1150 - 1157
06/01/2007 Authors: Mihelic R; Kaufman JL; Lonial S -
Tanespimycin (T) plus bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory patients
Volume: 92 Page(s): 156 - 156
06/01/2007 Authors: Richardson PG; Chanan-Khan A; Lonial S; Krishnan A; Carroll M; Cropp GF; Albitar M; Johnson RG; Hannah AL; Anderson KC -
Effect of Len/Dex in MM in different age groups
Volume: 92 Page(s): 172 - 173
06/01/2007 Authors: Lonial S; Knight R; Dimopoulos M; Chanan-Khan A; San Miguel J; Facon T; Yu Z; Zeldis J; Olesnyckyj M; Weber D -
Hematologic profiles with bortezomib in relapsed MM
Volume: 92 Page(s): 159 - 160
06/01/2007 Authors: Lonial S; Richardson PG; Miguel JS; Sonneveld P; Schuster M; Blade J; Cavenagh J; Rajkumar V; Jakubowiak A; Esseltine D -
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Volume: 137 Page(s): 429 - 435
06/01/2007 Authors: Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; San Miguel J-F -
Phase 1/2 study of upfront Rev/Vel/Dex in MM: Early results
Volume: 92 Page(s): 179 - 179
06/01/2007 Authors: Richardson RG; Jagannath S; Raje NS; Ghobrial IM; Schlossman RL; Mazumder A; Munshi NC; Vesole D; Doss D; McKenney ML -
A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: Preliminary results. Multiple myeloma research consortium (MMRC) trial
Volume: 92 Page(s): 154 - 155
06/01/2007 Authors: Jakubowiak A; Richardson P; Zimmerman T; Alsina M; Lonial S; Kendall T; Hideshima T; Sportelli P; Birch R; Henderson IC -
Phase 2 study of Rev/Vel/Dex in relapsed/refractory MM
Volume: 92 Page(s): 171 - 171
06/01/2007 Authors: Richardson PG; Jagannath S; Raje N; Ghobrial I; Schlossman RL; Mazumder A; Munshi NC; VeSole D; Colson K; McKenney ML -
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Cancer Res Volume: 67 Page(s): 4981 - 4988
05/15/2007 Authors: Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun S-Y -
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells.
Cancer Res Volume: 67 Page(s): 4973 - 4980
05/15/2007 Authors: Qiu Y; Liu X; Zou W; Yue P; Lonial S; Khuri FR; Sun S-Y -
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. (vol 47, pg 629, 2007)
TRANSFUSION Volume: 47 Page(s): 952 - 952
05/01/2007 Authors: Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi SS; Teagarden D; Hamilton ES; Waller EK -
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Transfusion Volume: 47 Page(s): 629 - 635
04/01/2007 Authors: Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK -
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.
Blood Volume: 109 Page(s): 2604 - 2606
03/15/2007 Authors: Chanan-Khan AA; Kaufman JL; Mehta J; Richardson PG; Miller KC; Lonial S; Munshi NC; Schlossman R; Tariman J; Singhal S -
Designing risk-adapted therapy for multiple myeloma: the Mayo perspective.
Mayo Clin Proc Volume: 82 Page(s): 279 - 281
03/01/2007 Authors: Lonial S -
A randomized phase I trial of melphalan plus bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
Volume: 13 Page(s): 56 - 56
02/01/2007 Authors: Lonial S; Kaufman J; Langston AA; Khoury HJ; Torre C; Lechowicz MJ; Flowers C; Waller EK -
Race and disparities in health.
Curr Probl Cancer Volume: 31 Page(s): 114 - 122
01/01/2007 Authors: Brawley OW; Jani AB -
Racial differences in the incidence and outcomes for patients with hematological malignancies.
Curr Probl Cancer Volume: 31 Page(s): 182 - 201
01/01/2007 Authors: Flowers CR; Glover R; Lonial S; Brawley OW -
Pharmacokinetic (PK) and pharmacodynamics (PD), study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma (MM).
Volume: 108 Page(s): 1008A - 1008A
11/16/2006 Authors: Stewart AK; Sullivan D; Lonial S; Mohrbacher AF; Chatta G; Shustik C; Burris H; Karol M; Zannikos P; Reece DE -
Analysis of varicella zoster virus reactivation among bortezomib treated patients in the APEX study.
Volume: 108 Page(s): 1009A - 1009A
11/16/2006 Authors: Chanan-Khan AA; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; Goldschmidt H -
Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
Volume: 108 Page(s): 554A - 554A
11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ -
Patients receiving patifermin in conjunction with melphalan 200 required fewer platelet transfusions: Analysis of a retrospective cohort study.
Volume: 108 Page(s): 407B - 407B
11/16/2006 Authors: Hutcherson DA; Langston A; Lin CH; Flowers C; Lechowicz MJ; Waller N; Sessions JK; Kaufman JL; Jean Khoury H; Lonial S -
Impact of revised international working group criteria on lymphoma patients undergoing autologous stem cell transplantation.
Volume: 108 Page(s): 873A - 873A
11/16/2006 Authors: Lucas AS; Flowers C; Langston A; Lonial S; Lechowicz MJ; Waller N; Kaufman JL; Jean Khoury H -
T cell reconstitution in first 200 days post transplantation predicts long term survival in allogeneic hematopoetic progenitor cell transplantation (HPCT).
Volume: 108 Page(s): 920A - 920A
11/16/2006 Authors: Vann L; Larks M; Flowers C; Lonial S; Kaufman J; Lechowicz MJ; Langston AA; Khoury J; Waller N -
Infliximab for the treatment of chronic graft versus host disease.
Volume: 108 Page(s): 818A - 818A
11/16/2006 Authors: Tolbert E; Waller N; Khoury HJ; Lechowicz MJ; Flowers C; Lonial S; Vann L; Langston A; Kaufman JL -
A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus G-CSF) on dendritic cell and T-Cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant.
Volume: 108 Page(s): 964A - 964A
11/16/2006 Authors: Lonial S; McMillan S; Torre C; Langston AA; Hamilton E; Cook A; Flowers C; Kaufman JL; Lechowicz MJ; Waller N -
Perifosine induces DR4/DR5 expression leading to apoptosis that can be enhanced with exogenous TRAIL, and blocked with strategies directed at DR4/DR5 inhibition.
Volume: 108 Page(s): 984A - 984A
11/16/2006 Authors: David E; Sinha R; Kaufman JL; Lonial S -
14-3-3 integrates pro-survival signals in hematopoietic cells transformed by diverse leukemogenic tyrosine kinases, and represents a common target.
Volume: 108 Page(s): 337A - 337A
11/16/2006 Authors: Dong S; Kang S; Gu T-L; Kardar S; Lonial S; Khoury HJ; Khuri F; Fu H; Chen J -
A vascular targeted pan PI-3 kinase inhibitor, SF1126 with activity against multiple myeloma in vivo.
Volume: 108 Page(s): 76A - 76A
11/16/2006 Authors: De P; Peng Q; Dey N; McDermitt B; Peng X; Garlich J; Lonial S; Durden DL -
FGFR3 activates RSK2 to mediate hematopoietic transformation through both tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.
Volume: 108 Page(s): 155A - 156A
11/16/2006 Authors: Kang S; Dong S; Gu T-L; Cohen MS; Lonial S; Khoury HJ; Gillilattd DG; Taunton J; Polakiewicz RD; Chen J -
A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM).
Volume: 108 Page(s): 1023A - 1023A
11/16/2006 Authors: Richardson P; Lonial S; Jakubowiak A; Wolf J; Krishnan A; Densmore J; Singhal S; Ghobrial I; Schwartzberg L; Colson K -
A multicenter phase 1 clinical trial of tanespimycin (KOS-953) + bortezomib (BZ): Encouraging activity and manageable toxicity in heavily pre-treated patients with relapsed refractory multiple myeloma (MM).
Volume: 108 Page(s): 124A - 125A
11/16/2006 Authors: Richardson P; Chanan-Khan AA; Lonial S; Krishnan A; Alsina M; Carroll M; Adler K; Cropp G; Mitsiades C; Johnson R -
Management of toxicities associated with bortezomib.
Oncology (Williston Park) Volume: 20 Page(s): 1592 - 1597
11/01/2006 Authors: Lonial S; Multiple Myeloma Research Foundation -
Management of toxicities associated with bortezomib - From the Multiple Myeloma Research Foundation
ONCOLOGY-NEW YORK Volume: 20 Page(s): 1592 - +
11/01/2006 Authors: Lonial S -
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
Volume: 24 Page(s): 4867 - 4874
10/20/2006 Authors: Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S -
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK -
Phase 1 clinical trial of KOS-953 plus bortezomib (BZ) in relapsed refractory multiple myeloma (MM).
Volume: 24 Page(s): 137S - 137S
06/20/2006 Authors: Chanan-Khan A; Richardson P; Alsina M; Lonial S; Krishnan A; Carroll M; Albitar M; Hannah AL; Johnson RG; Anderson K -
A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma.
J Clin Oncol Volume: 24 Page(s): 17550
06/20/2006 Authors: Kaufman JL; Waller EK; Torre C; McMillan S; Langston A; Flowers C; Lechowicz M; Tighiouart M; Lonial S -
Phase I trial of chir-258 in multiple myeloma.
J Clin Oncol Volume: 24 Page(s): 17502
06/20/2006 Authors: Lonial S; Alsina M; Anderson KC; Richardson P; Stewart K; Fonseca R; Heise C; Fox J; Allen A; Michelson G -
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Cancer Volume: 106 Page(s): 2171 - 2180
05/15/2006 Authors: Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S -
Novel treatment approaches for patients with relapsed and refractory multiple myeloma.
Curr Treat Options Oncol Volume: 7 Page(s): 246 - 257
05/01/2006 Authors: Sinha R; Lonial S -
Proteasome inhibition: novel therapy for multiple myeloma.
Onkologie Volume: 29 Page(s): 162 - 168
04/01/2006 Authors: Kaufman JL; Lonial S -
Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia
Volume: 12 Page(s): 69 - 70
02/01/2006 Authors: Arellano M; Flowers C; Waller E; Lonial S; Kaufman J; Winton E; Khoury H; Langston A -
Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors
Volume: 12 Page(s): 132 - 132
02/01/2006 Authors: Ninan MJ; Arellano M; Philip A; Langston A; Flowers CR; Lonial S; Kaufman J; Lechowicz M; Khoury JH; Roback J -
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
Clin Cancer Res Volume: 12 Page(s): 273 - 280
01/01/2006 Authors: Zou W; Yue P; Lin N; He M; Zhou Z; Lonial S; Khuri FR; Wang B; Sun S-Y -
Novel treatment approaches for patients with multiple myeloma.
Clin Lymphoma Myeloma Volume: 6 Page(s): 281 - 288
01/01/2006 Authors: Sinha R; Kaufman JL; Lonial S -
A practical update on the use of bortezomib in the management of multiple myeloma.
Oncologist Volume: 11 Page(s): 51 - 61
01/01/2006 Authors: San Miguel J; Blad J; Boccadoro M; Cavenagh J; Glasmacher A; Jagannath S; Lonial S; Orlowski RZ; Sonneveld P; Ludwig H -
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
Blood Volume: 106 Page(s): 4322 - 4329
12/15/2005 Authors: David E; Sun S-Y; Waller EK; Chen J; Khuri FR; Lonial S -
The Richardson/Schlossman/Hideshima et al article reviewed
ONCOLOGY-NEW YORK Volume: 19 Page(s): 1792 - +
12/01/2005 Authors: Kaufman JL; Lonial S -
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
Blood Volume: 106 Page(s): 3777 - 3784
12/01/2005 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Orlowski RZ; Giver CR; Jaye DL; Francis D; Giusti S; Torre C -
Bortezomib continues demonstrates superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: Updated results of the APEX trail.
Volume: 106 Page(s): 715A - 716A
11/16/2005 Authors: Richardson P; Sonneveld P; Schuster M; Irwin D; Stadtmauer E; Facon T; Harousseau J; Ben-Yehuda D; Lonial S; Goldschmidt H -
Hematologic profiles in the phase 3 APEX trial.
Volume: 106 Page(s): 970A - 970A
11/16/2005 Authors: Lonial S; Richardson P; Sonneveld P; Schuster M; Irwin D; Stadtmauer E; Facon T; Harousseau J; Ben-Yehuda D; Goldschmidt H -
Relapse free survival of elderly AML patients is comparable to that of younger adults when treated with a modified dose intensive cytarabine regimen.
Volume: 106 Page(s): 237B - 237B
11/16/2005 Authors: Langston AA; Heffner LT; Hutcherson D; Neely J; Flowers C; Waller EK; Lonial S; Khoury HJ; Winton E -
Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial.
Volume: 106 Page(s): 111A - 111A
11/16/2005 Authors: San Miguel JF; Richardson P; Sonneveld P; Schuster M; Irwin D; Stadtmauer E; Facon T; Harousseau J; Ben-Yehuda D; Lonial S -
Decreased incidence of relapse in patients with acute leukemia transplanted from matched unrelated donors: Induction of GvL
Volume: 106 Page(s): 570A - 571A
11/16/2005 Authors: Arellano ML; Langston A; Lonial S; Flowers C; Khoury JH; Winton E; Waller EK; Mary LJ -
A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus GCSF) on dendritic cell and T-cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant
Volume: 106 Page(s): 555A - 555A
11/16/2005 Authors: Lonial S; Torre C; Langston AA; McMillans S; Hamilton E; Flowers C; Lechowicz MJ; Waller EK -
Combination of Akt/PKB inhibition (perifosine) and farnesyl transferase inhibition (tipifarnib) results in increased cell death in myeloma cells lines.
Volume: 106 Page(s): 450A - 450A
11/16/2005 Authors: Sinha R; David E; Zeilter E; Torre C; Kaufman JL; Lonial S -
Phase 1 clinical trial of KOS-953+Bortezomib (BZ) in relapsed refractory multiple myeloma (MM)
Volume: 106 Page(s): 109A - 110A
11/16/2005 Authors: Chanan-Khan AA; Richardson PG; Alsina M; Carroll M; Lonial S; Krishnan A; Albitar M; Zhou Y; Mitsiades C; Cropp G -
Patient characteristics in CD 20(+) and CD 20(-) adult acute lymphoblastic leukemia (ALL): A single institution analysis.
Volume: 106 Page(s): 210B - 210B
11/16/2005 Authors: Gladney SP; Heffner LT; Langston A; Holden J; Phillips C; Winton E; Flowers CR; Lechowicz MJ; Lonial S; Waller E -
Enhanced levels of apoptosis by combination of farnesyl transferase inhibition (tipifarnib) and proteasome inhibition (bortezomib) in myeloma cell lines and primary myeloma cells and its mechanistic effects on Akt and caspase pathways.
Volume: 106 Page(s): 451A - 452A
11/16/2005 Authors: Kaufman JL; David E; Torre C; Sinha R; Lonial S -
Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis.
Volume: 106 Page(s): 716A - 717A
11/16/2005 Authors: Chanan-Khan AA; Richardson P; Lonial S; Siegel D; Jagannath S; Mehta J; Doran J; Singhal S -
Combination of farnesyl transferase inhibitor (Tipifarnib) with perifosine induces apoptosis through phos-PDK1 in human lymphoma and leukemia cell lines.
Volume: 106 Page(s): 428A - 429A
11/16/2005 Authors: David E; Sinha R; Torre C; Kaufman JL; Lonial S -
Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.
Expert Opin Investig Drugs Volume: 14 Page(s): 1161 - 1169
09/01/2005 Authors: Haas M; Lonial S -
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
N Engl J Med Volume: 352 Page(s): 2487 - 2498
06/16/2005 Authors: Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau J-L; Ben-Yehuda D; Lonial S; Goldschmidt H -
Results of a clinical phase I dose-escalation study of cylarabine in combination with fixed dose vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for the treatment of relapsed/refractory lymphoma.
Volume: 23 Page(s): 607S - 607S
06/01/2005 Authors: Arellano ML; Lonial S; Langston A; Flowers C; Heffner T; Hutcherson D; Winton E; Waller E -
Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity.
Volume: 23 Page(s): 587S - 587S
06/01/2005 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Orlowski RZ; Giver CR; Jaye DL; Barlogie B; Heffner LT; Anderson KC -
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma
Volume: 23 Page(s): 568S - 568S
06/01/2005 Authors: Richardson PG; Sonneveld P; Schuster MW; Irwin D; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Anderson KC -
Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity.
Expert Opin Biol Ther Volume: 5 Page(s): 293 - 311
03/01/2005 Authors: Everly JJ; Lonial S -
Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma
Volume: 11 Page(s): 6 - 6
02/01/2005 Authors: Kaufman JL; Lonial S; Hicks M; Langston A; Flowers C; Lechowicz MJ; Khoury H; Waller EK -
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Biol Blood Marrow Transplant Volume: 10 Page(s): 848 - 857
12/01/2004 Authors: Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK -
Predictors of more rapid lymphoid reconstitution after allogeneic transplantation
Volume: 104 Page(s): 864A - 864A
11/16/2004 Authors: Arellano ML; Moore SG; Kudchadkar R; Flowers CR; Langston AA; Lonial S; Lechowicz MJ; Waller EK -
Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: Final report of the APEX study
Volume: 104 Page(s): 108A - 108A
11/16/2004 Authors: Richardson P; Sonneveld P; Schuster M; Irwin D; Stadtmauer E; Facon T; Harousseau J; Ben-Yehuda D; Lonial S; Goldschmidt H -
A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
Volume: 104 Page(s): 502A - 502A
11/16/2004 Authors: Langston AA; McMillan S; Lonial S; Smith K; Waller EK; Heffner LT; Bucur S; Redei I; Flowers C; Lechowicz MJ -
Donor dendritic cells regulate immune reconstitution after allogeneic bone marrow transplantation.
Volume: 104 Page(s): 839A - 840A
11/16/2004 Authors: Li JM; Harris W; David E; Lonial S; Waller N -
A randomized trial to evaluate the impact of cytokines on dendritic cell, T-cell and T-cell function when mobilizing normal donors for allogeneic progenitor cell transplant: An interim analysis.
Volume: 104 Page(s): 780A - 780A
11/16/2004 Authors: Lonial S; Torre C; Hicks M; Mcmillan S; Langston AA; Flowers CR; Lechowicz MJ; Waller EK -
Combination of farnesyl transferase inhibition (lonafarnib) and proteasome inhibition (bortezomib) results in rapid caspase activation and down regulation of p-AKT in myeloma cell lines and primary myeloma cells.
Volume: 104 Page(s): 678A - 678A
11/16/2004 Authors: David E; Sun SY; Khuri FR; Lonial S -
Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
Volume: 33 Page(s): 196 - 197
11/01/2004 Authors: Waller E; Giver C; Somani J; Langston A; Lonial S; Roback J; Jian ML; Hossain M; Redei I -
Multiple myeloma: The role of transplant and novel treatment strategies
Volume: 31 Page(s): 99 - 105
04/01/2004 Authors: Kaufman J; Lonial S -
The Winship Cancer Institute of Emory University presents proceedings from the 3rd annual updates in hematology and oncology, July 2003, Sea Island, Georgia - Introduction
SEMINARS IN ONCOLOGY Volume: 31 Page(s): 1 - 2
04/01/2004 Authors: Lonial S -
Multiple myeloma: the role of transplant and novel treatment strategies.
Semin Oncol Volume: 31 Page(s): 99 - 105
04/01/2004 Authors: Kaufman J; Lonial S -
Donor antigen-presenting cells regulate graft-versus-leukaemia effects after allogeneic transplantation
Volume: 33 Page(s): S18 - S18
03/01/2004 Authors: Waller E; Li J; Lonial S -
Optimization of chemo-mobilization of autologous blood hematopoietic progenitor cell grafts
Volume: 10 Page(s): 64 - 65
02/01/2004 Authors: Hicks ML; Lonial S; Langston A; Smith KJ; Sai SM; Hamilton ES; Waller EK -
Reconstructing immunity after allogeneic transplantation.
Immunol Res Volume: 29 Page(s): 269 - 282
01/01/2004 Authors: Giver CR; Li J-M; Hossain MS; Lonial S; Waller EK -
Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
Blood Cells Mol Dis Volume: 33 Page(s): 233 - 237
01/01/2004 Authors: Waller EK; Giver CR; Rosenthal H; Somani J; Langston AA; Lonial S; Roback JD; Li J-M; Hossain MS; Redei I -
Immunomodulation: the role of hematopoietic cytokines.
Support Cancer Ther Volume: 1 Page(s): 80 - 88
01/01/2004 Authors: Lonial S -
Early autologous transplantation for mantle cell lymphoma may improve long term disease-free survival.
Volume: 102 Page(s): 734A - 735A
11/16/2003 Authors: Murali S; Lonial S; Redei I; Smith K; Waller EK; Heffner LT; Bucur S; Winton E; Manion K; Langston A -
Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma.
Volume: 102 Page(s): 447A - 447A
11/16/2003 Authors: Lonial S; Waller EK; Richardson PG; Jagannath S; Francis D; Lehman M; Torre C; Barlogie B; Berenson JR; Singhal S -
Modulation of allogeneic PBPC graft contents using G-CSF or G-CSF+GM-CSF: Preliminary results from a randomized trial.
Volume: 102 Page(s): 953A - 953A
11/16/2003 Authors: Lonial S; Torre C; Hicks M; Tanner A; Langston AA; Redei I; Waller EK -
A phase I study of dose escalated cytarabine in combination with a modified ESHAP-like regimen, paclitaxel, and vinorelbine (VTEPA) for the treatment of relapsed/refractory lymphoma.
Volume: 102 Page(s): 293B - 293B
11/16/2003 Authors: Lonial S; Tanner A; Langston AA; Redei I; Heffner LT; Bucur SZ; Hutcherson D; Winton E; Waller EK -
Safety of voriconazole after autologous and allogeneic stem cell transplantation.
Volume: 102 Page(s): 454B - 454B
11/16/2003 Authors: Restrepo MH; Langston AA; Shayani S; Waller EK; Lonial S -
Bortezomib inhibits T cell proliferation.
Volume: 102 Page(s): 61B - 61B
11/16/2003 Authors: Kaufman JL; Waller EK; Torre C; Boswell MG; Lonial S -
A phase I trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
Volume: 102 Page(s): 333B - 333B
11/16/2003 Authors: Langston AA; Tanner A; Lonial S; Heffner LT; Smith K; Bucur S; Waller EK; Redei I; Winton E -
Optimal timing for chemotherapy and cytokine mobilization of autologous blood hematopoietic progenitor cells.
Volume: 102 Page(s): 419B - 419B
11/16/2003 Authors: Hicks ML; Lonial S; Langston A; Smith KJ; Sai SM; Hamilton ES; Waller EK -
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Biol Blood Marrow Transplant Volume: 9 Page(s): 616 - 632
10/01/2003 Authors: Giver CR; Montes RO; Mittelstaedt S; Li J-M; Jaye DL; Lonial S; Boyer MW; Waller EK -
Hematopoietic cytokines: when treating the symptoms does not treat the disease.
Support Cancer Ther Volume: 1 Page(s): 36 - 37
10/01/2003 Authors: Lonial S -
Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.
Biol Blood Marrow Transplant Volume: 9 Page(s): 460 - 471
07/01/2003 Authors: Waller EK; Langston AA; Lonial S; Cherry J; Somani J; Allen AJ; Rosenthal H; Redei I -
Signal transduction and myeloma: new targets, new hope.
Cancer Biol Ther Volume: 2 Page(s): 310 - 319
01/01/2003 Authors: Lonial S; Waller EK; Simons JW; Heffner LT -
Breakthroughs in the management of multiple myeloma.
Drugs Volume: 63 Page(s): 1621 - 1636
01/01/2003 Authors: Heffner LT; Lonial S -
A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses.
Vaccine Volume: 21 Page(s): 221 - 230
12/13/2002 Authors: Somani J; Lonial S; Rosenthal H; Resnick S; Kakhniashvili I; Waller EK -
Three methods of T-cell depletion of HPCT products: Analysis of CD34+ cell and lymphocyte purity and recovery.
Volume: 100 Page(s): 835A - 836A
11/16/2002 Authors: Lonial S; Rizzieri DA; Koh LP; Jones M; Langston AA; Redei I; Long GD; Gasparetto C; Vredenburgh JJ; Waller EK -
2ME-2 inhibits microtubule polymerization and HIF-1 nuclear accumulation in human myeloma and bone marrow stromal cells.
Volume: 100 Page(s): 393B - 393B
11/16/2002 Authors: Lonial S; Escuin D; LaVallee T; Giannakakou P -
Depletion of monocytes and DC2 enhances T-cell proliferation and IL12 production in response to allo-antigen: Implications for allogeneic transplantation.
Volume: 100 Page(s): 615A - 615A
11/16/2002 Authors: Stuebner M; Torre C; Waller EK; Lonial S -
Fludarabine treatment of allogeneic donor lymphocytes selects for Th2 regulatory T-cells and reduces GvHD activity in MHC mis-matched murine BMT.
Volume: 100 Page(s): 824A - 825A
11/16/2002 Authors: Giver CR; Montes RO; Mittelstaedt S; Jaye DL; Lonial S; Li JM; Boyer MW; Waller EK -
Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma.
Volume: 100 Page(s): 178A - 178A
11/16/2002 Authors: Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S -
Indirect antigen presentation is more effective when the responder T-cell population is naive not memory T-cells.
Volume: 100 Page(s): 58B - 59B
11/16/2002 Authors: Lonial S; Torre C; Stuebner M; Waller EK -
Effect of donor dendritic cells on overall survival and incidence of GvHD after allogeneic HPCT from HLA matched sibling donors.
Volume: 100 Page(s): 420A - 421A
11/16/2002 Authors: Gladney SP; Waller EK; Redei I; Langston AA; Lonial S -
Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donors.
Bone Marrow Transplant Volume: 30 Page(s): 335 - 340
09/01/2002 Authors: Redei I; Langston AA; Lonial S; Cherry JK; Allen AJ; Hamilton E; Jones M; Bartlett VM; Waller EK -
Ex-vivo exposure to fludarabine reduces allo-proliferation and preserves homeostatic proliferation of donor T-cells in MHC mismatched transplants
Volume: 30 Page(s): 86 - 86
06/01/2002 Authors: Giver C; Montes RO; Mittelstaedt S; Lonial S; Li JM; Boyer MW; Waller EK -
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.
Blood Volume: 99 Page(s): 1085 - 1088
02/01/2002 Authors: Langston AA; Redei I; Caliendo AM; Somani J; Hutcherson D; Lonial S; Bucur S; Cherry J; Allen A; Waller EK -
DC2 effect on survival following allogeneic bone marrow transplantation.
Oncology (Williston Park) Volume: 16 Page(s): 19 - 26
01/01/2002 Authors: Waller EK; Rosenthal H; Sagar L -
CD34 selection of peripheral blood progenitor cells for autologous transplant in myeloma and amyloidosis is associated with an increased risk of post-transplant varicella Zoster.
BLOOD Volume: 98 Page(s): 392A - 392A
11/16/2001 Authors: Smith KJ; Hamilton ES; Waller EK; Langston AA; Redei I; Lonial S; Heffner LT -
Infectious outcomes after alternative donor stem cell transplantation: A retrospective cohort study.
BLOOD Volume: 98 Page(s): 205A - 205A
11/16/2001 Authors: Somani J; Redei I; Cherry J; Tanner A; Lonial S; Bartlett V; Manion K; Waller EK; Langston AA -
Non-fatal Veno-Occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin).
BLOOD Volume: 98 Page(s): 201B - 202B
11/16/2001 Authors: Langston AA; Feinstein B; Hutcherson D; Heffner LT; Redei I; Smith K; Lonial S; Bucur S; Jones A; Waller EK -
Modulation of allo-reactivity of human PBMC by ex vivo treatment with fludarabine.
BLOOD Volume: 98 Page(s): 341B - 342B
11/16/2001 Authors: Lonial S; Torre C; Rosenthal H; Giver CR; Waller EK -
Fludarabine-treated donor lymphocytes: A novel method to reduce GvHD that preserves graft facilitating and graft v. leukemia activity.
BLOOD Volume: 98 Page(s): 324B - 325B
11/16/2001 Authors: Giver CR; Li JM; Montes RO; Lonial S; Waller N -
Comparison of partially mismatched related donor (PMRD) graft vs volunteer unrelated donor (VUD) transplant for high risk hematologic malignancies.
BLOOD Volume: 98 Page(s): 386B - 386B
11/16/2001 Authors: Redei I; Langston AA; Jones M; Tanner A; Teagarden D; Lonial S; Cherry J; Bartlett V; Waller EK -
Thymoglobulin pharmicokinetics and immune reconstitution in recipients of T-cell depleted CD34+transplants from HLA mis-matched donors.
BLOOD Volume: 98 Page(s): 670A - 670A
11/16/2001 Authors: Waller N; Langston A; Lonial S; Allen A; Cherry J; Rosenthal HS; Redei I -
Yield of surveillance blood cultures in patients on corticosteroids for graft-versus-host disease.
BLOOD Volume: 98 Page(s): 362B - 362B
11/16/2001 Authors: Somani J; Teagarden D; Mossavi-sai S; Thourani J; Redei I; Lonial S; Waller EK; Langston AA -
Immature DC1 and DC2 progenitors induce divergent allo-immune responses in autologous naive T-cells via indirect antigen presentation.
BLOOD Volume: 98 Page(s): 37B - 37B
11/16/2001 Authors: McDougal V; Rosenthal H; Torre C; Waller EK; Lonial S -
Salvage therapy with Infliximab for patients with severe acute and chronic GvHD.
BLOOD Volume: 98 Page(s): 399A - 399A
11/16/2001 Authors: Redei I; Knoche J; Tanner AR; Langston AA; Lonial S; Cherry JK; Sai SM; Waller EK -
A randomized, placebo-controlled trial of GM-CSF as a vaccine adjuvant: Effect on cellular and humoral immune response
CLINICAL INFECTIOUS DISEASES Volume: 33 Page(s): 1154 - 1154
10/01/2001 Authors: Somani T; Lonial S; Rosenthal H; Waller EK -
Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation.
Blood Volume: 97 Page(s): 2948 - 2956
05/15/2001 Authors: Waller EK; Rosenthal H; Jones TW; Peel J; Lonial S; Langston A; Redei I; Jurickova I; Boyer MW -
Changes in the pattern of TCR V beta repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans.
Br J Haematol Volume: 113 Page(s): 224 - 230
04/01/2001 Authors: Lonial S; Bomberger C; Waller EK -
Sequential CD34+and CD3+allogeneic cell transplants in patients with poor risk hematologic malignancies.
BLOOD Volume: 96 Page(s): 359B - 359B
11/16/2000 Authors: Waller EK; Langston AA; Bucur S; Lonial S; Cherry J; Feinstein B; Redei I -
A randomized study of G-CSF vs the combination of G-CSF/GM-CSF on mobilization of dendritic cells in peripheral stem cell grafts.
BLOOD Volume: 96 Page(s): 518A - 518A
11/16/2000 Authors: Lonial S; Rosenthal H; Feinstein B; Cherry J; Dunzel M; Waller EK -
Chronic GVHD (cGVHD) after matched sibling BMT is predicted by the number of transplanted donor NK-like T cells.
BLOOD Volume: 96 Page(s): 200A - 200A
11/16/2000 Authors: Langston A; Jones TW; Rosenthal H; Redei I; Lonial S; Waller EK -
High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma.
Leuk Lymphoma Volume: 36 Page(s): 497 - 502
02/01/2000 Authors: Lonial S; Jones TW; Devine S; Winton EF; Heffner LT; Smith KJ; Yeager AM; Waller EK -
Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature.
Bone Marrow Transplant Volume: 24 Page(s): 1337 - 1341
12/01/1999 Authors: Lonial S; Bilodeau PA; Langston AA; Lewis C; Mossavi-Sai S; Holden JT; Waller EK -
Survival analysis of allogeneic bone marrow transplant (BMT) with and without GM-CSF support, a retrospective analysis of 182 patient.
BLOOD Volume: 94 Page(s): 151A - 151A
11/15/1999 Authors: Lonial S; Langston AA; Jones TW; Ennis SD; Waller EK -
Fludarabine attenuates the GvHD potential of allogeneic lymphocytes in BMT.
BLOOD Volume: 94 Page(s): 323B - 323B
11/15/1999 Authors: Mittelstaedt S; Montes R; Lonial S; Hairston R; Redei I; Boyer M; Waller EK -
Modified high dose Ara-C (mHiDAC) and daunorubicin as induction therapy for newly diagnosed AML without t(15;17).
BLOOD Volume: 94 Page(s): 233B - 233B
11/15/1999 Authors: Lonial S; Langston AA; Bhalla K; Smith KJ; Heffner LT; Bucur S; Hutcherson DA; Winton EF -
Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.
Blood Volume: 94 Page(s): 3222 - 3233
11/01/1999 Authors: Waller EK; Ship AM; Mittelstaedt S; Murray TW; Carter R; Kakhniashvili I; Lonial S; Holden JT; Boyer MW -
Vaccination with Td increases the frequency of antigen specific T-cells in the peripheral blood using a FACS analysis of intracellular IL2 expression.
BLOOD Volume: 92 Page(s): 339A - 339A
11/15/1998 Authors: Lonial S; Somani J; Resnick S; Kakhniashvili I; Rosenthal H; Ship A; Waller EK -
Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient.
Bone Marrow Transplant Volume: 19 Page(s): 753 - 755
04/01/1997 Authors: Lonial S; Williams L; Carrum G; Ostrowski M; McCarthy P